<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>&lt;i&gt;Mycoplasma pneumoniae&lt;/i&gt; infection in adults</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center"><i>Mycoplasma pneumoniae</i> infection in adults</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle"><i>Mycoplasma pneumoniae</i> infection in adults</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Stephen G Baum, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Thomas M File, Jr, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sheila Bond, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 03, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H325624898"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span><em>Mycoplasma pneumoniae</em> is one of the smallest free-living organisms and a common bacterial respiratory tract pathogen. Upper respiratory tract infections and acute bronchitis are the most common manifestations of <em>M. pneumoniae</em> infection, but pneumonia can also occur. Manifestations outside the respiratory tract (eg, encephalitis, hemolytic anemia, and carditis) are rare and can occur with respiratory tract infections or independently.</p><p>The clinical features, diagnosis, and treatment of infections, primarily pneumonia, caused by <em>M. pneumoniae</em> in adults will be reviewed here. <em>M. pneumoniae</em> infections in children as well as <em>Mycoplasma hominis</em> infections are discussed separately. (See  <a class="medical medical_review" href="/d/html/6070.html" rel="external">"<i>Mycoplasma pneumoniae</i> infection in children"</a> and  <a class="medical medical_review" href="/d/html/5508.html" rel="external">"<i>Mycoplasma hominis</i> and <i>Ureaplasma </i>infections"</a>.)</p><p class="headingAnchor" id="H1325403642"><span class="h1">MICROBIOLOGY</span><span class="headingEndMark"> — </span>The term "mycoplasma" is widely used to refer to any organism within the class Mollicutes, which is composed of five genera (<em>Mycoplasma</em>, <em>Ureaplasma</em>, <em>Acholeplasma</em>, <em>Anaeroplasma</em>, and <em>Asteroleplasma</em>). Mycoplasmas are bacteria and are the smallest free-living organisms.</p><p>Over 120 named <em>Mycoplasma</em> species exist and 13 <em>Mycoplasma</em> species, 2 <em>Acholeplasma</em> species, and 1 <em>Ureaplasma</em> species have been isolated from humans. However, only four species are well-established human pathogens [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><em>M. pneumoniae</em></p><p class="bulletIndent1"><span class="glyph">●</span><em>M. hominis</em></p><p class="bulletIndent1"><span class="glyph">●</span><em>Mycoplasma genitalium</em></p><p class="bulletIndent1"><span class="glyph">●</span><em>Ureaplasma urealyticum</em></p><p></p><p><em>Mycoplasma amphoriforme</em> is less well-established as a human pathogen but has been reported to cause relapsing pneumonia through person-to-person spread in both immunocompetent and patients with primary antibody deficiency [<a href="#rid2">2,3</a>].</p><p>Among <em>Mycoplasma</em> species, <em>M. pneumoniae</em> is the most common cause of human respiratory illness. The organism is a short rod that lacks a cell wall. Because it lacks a cell wall, <em>M. pneumoniae</em> is not visible on Gram stain and is not susceptible to beta-lactams and other antibiotics that inhibit cell wall synthesis. These features designate <em>M. pneumoniae</em> as an "atypical" pathogen.</p><p class="headingAnchor" id="H2"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>The mechanisms by which mycoplasmas produce infection are becoming better understood. Pathogenic mycoplasmas possess specialized tip organelles that mediate their interactions with host cells through a P1 adhesin protein that contributes to adherence and gliding motility along the respiratory epithelium [<a href="#rid4">4-6</a>].</p><p><em>M. pneumoniae</em> most commonly exists in a filamentous form, and its adherence proteins attach to epithelial membranes with particular affinity for the respiratory tract [<a href="#rid7">7,8</a>]. Once attached, <em>M. pneumoniae</em> produces hydrogen peroxide and superoxide, causing injury to epithelial cells and their associated cilia. Toll-like receptor 2 is also believed to be important for binding of <em>Mycoplasma</em> and activation of inflammatory mediators, including cytokines [<a href="#rid9">9-11</a>]. Robust immune responses, especially, production of interleukin 17, may play a role in the severity of disease [<a href="#rid12">12</a>]. Host-adapted survival is achieved by surface parasitism of target cells, the acquisition of essential biosynthetic precursors, and, in some cases, cell entry and intracellular survival [<a href="#rid13">13</a>].</p><p>There are two major subtypes of <em>M. pneumoniae</em>, type 1 and type 2, which differ in their P1 adhesin gene sequence [<a href="#rid14">14</a>]. Type 2 strains exhibit higher expression of community-acquired respiratory distress syndrome toxin, which has been shown to be a virulence factor causing vacuolization and which may play a role in respiratory epithelial destruction [<a href="#rid15">15-18</a>]. In addition, type 2 elaborates a more robust biofilm, which may protect the organism against antimicrobial penetration and host immune response [<a href="#rid19">19</a>].</p><p>Some of the pathogenic features of <em>M. pneumoniae</em> infection, particularly those that occur outside of the respiratory tract (eg, hemolysis, encephalitis) are believed to be immune mediated rather than caused by direct bacterial invasion [<a href="#rid8">8,20</a>]. Antibodies produced against the glycolipid antigens of <em>M. pneumoniae</em> may act as autoantibodies, since they cross-react with human brain cells and erythrocytes [<a href="#rid21">21</a>], as manifested in the cold agglutination phenomenon. (See <a class="local">'Hemolysis'</a> below.)</p><p>Following acute infection, prolonged asymptomatic carriage can develop [<a href="#rid22">22-24</a>]. While the mechanisms that mediate prolonged carriage are poorly understood, intracellular invasion, bacterial-induced cytoskeleton rearrangement, and tissue remodeling may be contributing factors [<a href="#rid24">24</a>]. Antibodies against <em>M. pneumoniae</em> made during acute infection seem to prevent against adhesion to respiratory epithelium, but these antibodies do not play a role in preventing chronic carriage [<a href="#rid25">25</a>].</p><p class="headingAnchor" id="H3"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span><em>M. pneumoniae</em> is endemic worldwide and causes both sporadic and epidemic infections.</p><p class="headingAnchor" id="H3323835212"><span class="h2">Incidence and prevalence</span><span class="headingEndMark"> — </span><em>M. pneumoniae</em> is among the most common bacterial causes of upper respiratory tract infection (URI), acute bronchitis, and community-acquired pneumonia (CAP). Serologic surveys suggest that approximately 1 percent of the United States population is infected with <em>M. pneumoniae </em>annually [<a href="#rid26">26</a>]. However, the incidence of specific clinical manifestations (eg, URI, acute bronchitis) are difficult to estimate as these infections are often mild and underdiagnosed.</p><p>Although URI and acute bronchitis are more common manifestations, the epidemiology of pneumonia has been better studied [<a href="#rid27">27-38</a>]. Based on epidemiologic studies that have used molecular techniques for the microbiologic diagnosis of CAP, estimates of <em>M. pneumoniae</em> infection range from 2 to 12 percent among adults with CAP [<a href="#rid36">36,38</a>]. During epidemic periods, rates can rise considerably. (See <a class="local">'Outbreaks'</a> below.)</p><p>Generally, CAP caused by <em>M. pneumoniae</em> is more common in young children than in adolescents and adults [<a href="#rid39">39</a>]. As an example, in a United States Centers for Disease Control and Prevention (CDC) surveillance study evaluating 2259 adults hospitalized with CAP over a two-year time period, <em>M. pneumoniae</em> was detected in 2 percent of cases [<a href="#rid36">36</a>]. By contrast, in a companion study evaluating 2359 children hospitalized with CAP over the same time period, <em>M. pneumoniae</em> was detected in 7.5 percent of cases [<a href="#rid40">40</a>]. <em>M. pneumoniae</em> was more common among children aged ≥5 years than among younger children (19 versus 3 percent).</p><p>Clinically significant manifestations rarely occur outside the respiratory tract.</p><p class="headingAnchor" id="H1007481092"><span class="h2">Transmission</span><span class="headingEndMark"> — </span><em>M. pneumoniae </em>is primarily transmitted from person to person via respiratory droplets. The incubation period after exposure averages two to three weeks [<a href="#rid41">41</a>]. While <em>M. pneumoniae</em> infections occur year round, rates tend to rise in summer and peak in late fall or winter during nonepidemic periods [<a href="#rid21">21,36,40,42-44</a>].</p><p class="headingAnchor" id="H950437477"><span class="h2">Outbreaks</span><span class="headingEndMark"> — </span>Epidemics tend to occur every few years [<a href="#rid42">42,44-47</a>]. Because <em>M. pneumoniae</em> is spread via respiratory droplets, epidemics frequently arise among persons living in close quarters. As examples, epidemics have been reported in households [<a href="#rid48">48</a>], schools [<a href="#rid49">49</a>], universities [<a href="#rid50">50-52</a>], health care facilities [<a href="#rid53">53-55</a>], and the military [<a href="#rid56">56-58</a>]. Based on household outbreaks, cumulative attack rates among persons living in close quarters can be as high as 90 percent [<a href="#rid26">26</a>].</p><p>Epidemics can extend into the community, encompass broad geographic regions, and persist for months to years [<a href="#rid59">59,60</a>]. Epidemics in a given geographic region tend to begin in winter months in countries of highest latitude and spread southward [<a href="#rid61">61</a>]. As an example, a marked rise in <em>M. pneumoniae</em> infections occurred in several northern European countries (ie, United Kingdom, Ireland, Norway, Sweden, Finland, Denmark, Germany, France) from 2010 to 2011 [<a href="#rid62">62-65</a>]. During this period, <em>M. pneumoniae</em> was estimated to cause 10 to 13 percent of CAP cases. In the three-year period following the epidemic, rates decreased to 1 to 2 percent [<a href="#rid60">60,62-65</a>].</p><p>Epidemics offer the opportunity to study risk factors for symptomatic infection. In an outbreak in a military unit, 41 of 91 trainees (45 percent) developed <em>M. pneumoniae</em> respiratory tract infections [<a href="#rid57">57</a>]. Among them, 10 (11 percent of all trainees) developed pneumonia. Smoking and low pre-existing <em>Mycoplasma</em>-specific immunoglobulin (Ig)G were independently associated with symptomatic infection (adjusted odds ratio [aOR] 5.6, 95% CI 1.5-20.4 and 7.8, 95% CI 1.3-42.5, respectively).</p><p class="headingAnchor" id="H6"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>The spectrum of illness associated with <em>M. pneumoniae</em> infection is wide [<a href="#rid66">66</a>]. Infection is often asymptomatic [<a href="#rid22">22,41</a>]. When infection is symptomatic, the most common manifestations include upper respiratory tract infection (URI), acute bronchitis, and pneumonia. Although a broad range of manifestations that do not involve the respiratory tract have been associated with <em>M. pneumoniae</em> infection, they are rare [<a href="#rid41">41,67</a>].</p><p class="headingAnchor" id="H3994428539"><span class="h2">Asymptomatic carriage</span><span class="headingEndMark"> — </span>Asymptomatic infection appears to be common, and prolonged carriage can occur following symptomatic infection [<a href="#rid22">22,23,57,68-70</a>]. Carriage rates in healthy persons range widely in epidemiologic studies, from approximately 0 to 50 percent [<a href="#rid22">22,23,68,71</a>]. Variance among studies likely reflects differences in local prevalence, patient age, diagnostic assays used, and study sample size. Following acute infection, asymptomatic carriage can persist for weeks to months, with a median duration of approximately seven weeks [<a href="#rid22">22,23,46</a>].</p><p>Studies using nucleic acid-based assays have demonstrated the presence of <em>M. pneumoniae</em> deoxyribonucleic acid (DNA) in the respiratory secretions of asymptomatic individuals with no recent history of respiratory illness, indicating the existence of a carrier state. The prevalence of this state is to be determined but may play a significant role in <em>M. pneumoniae</em> transmission [<a href="#rid22">22</a>]. (See <a class="local">'Transmission'</a> above.)</p><p class="headingAnchor" id="H7"><span class="h2">Respiratory tract disease</span></p><p class="headingAnchor" id="H3800779186"><span class="h3">URI and acute bronchitis</span><span class="headingEndMark"> — </span>Upper respiratory tract infection (URI) and acute bronchitis are the most common syndromes associated with <em>M. pneumoniae</em> infection [<a href="#rid67">67,72,73</a>]. The clinical features associated with URI and acute bronchitis caused by <em>M. pneumoniae</em> are similar to those caused by other pathogens.</p><p>URI symptoms associated with <em>M. pneumoniae</em> infection include cough, sore throat, rhinorrhea, coryza, and ear pain [<a href="#rid20">20,72</a>]. Cough is typically a dominant symptom and can be nonproductive or productive [<a href="#rid52">52,72</a>]. Wheezing can accompany the cough. The cough can be intractable or prolonged, which is the hallmark of acute bronchitis. Dyspnea is uncommon in the absence of pneumonia. Sinusitis can co-occur with respiratory symptoms but is typically clinically inapparent [<a href="#rid20">20</a>]. Like URIs and acute bronchitis caused by other pathogens (eg, respiratory viruses), URI and acute bronchitis caused by <em>M. pneumoniae</em> are typically self-limited; microbiologic testing and antibiotic treatment are usually unnecessary. (See  <a class="medical medical_review" href="/d/html/6865.html" rel="external">"The common cold in adults: Diagnosis and clinical features"</a> and  <a class="medical medical_review" href="/d/html/6870.html" rel="external">"Acute bronchitis in adults", section on 'Clinical features'</a>.)</p><p class="headingAnchor" id="H4082845474"><span class="h3">Pneumonia</span><span class="headingEndMark"> — </span>Pneumonia is a less common manifestation of <em>M. pneumoniae</em> infection, affecting about 3 to 10 percent of patients with respiratory tract disease [<a href="#rid72">72</a>]. Pneumonia caused by <em>M. pneumoniae</em> is often termed an "atypical pneumonia," which may refer to its mild nature or alternatively to the intrinsic resistance of <em>M. pneumoniae</em> to penicillins.</p><p><em>M. pneumoniae</em> pneumonia is typically community acquired and mild. Signs and symptoms vary with stage of illness  (<a class="graphic graphic_figure graphicRef59329" href="/d/graphic/59329.html" rel="external">figure 1</a>). Illness onset is gradual and may be heralded by headache, malaise, low-grade fever, and sometimes sore throat [<a href="#rid21">21,33,41,52,66</a>]. Cough (either productive or nonproductive) typically follows and may be accompanied by pleuritic chest pain or shortness of breath [<a href="#rid33">33</a>]. Chest soreness from persistent coughing is a common complaint. Other signs and symptoms of URI (eg, rhinorrhea, otitis media, sinusitis, cervical lymphadenopathy) can co-occur with pneumonia. Dyspnea, hypoxemia, hypotension, and altered mental status may be less common when compared with CAP caused by other pathogens [<a href="#rid33">33,41</a>].</p><p>Chest auscultation may be unremarkable early in the course of the disease; rales and wheezes may develop later [<a href="#rid41">41</a>]. Chest imaging tends to show reticular nodular opacities or patchy consolidations rather than large or lobar consolidations (see <a class="local">'Chest radiograph'</a> below). While the presence of these features support the diagnosis of <em>M. pneumoniae</em> pneumonia, none are pathognomonic and the diagnosis cannot be made without testing. (See <a class="local">'Pneumonia'</a> below.)</p><p>Compared with pneumonia caused by other pathogens, <em>M. pneumoniae</em> pneumonia is more commonly associated with mild extrapulmonary phenomena. For example, over half of patients have evidence of hemolysis, though this is often subclinical (see <a class="local">'Hemolysis'</a> below). Mild hepatic transaminitis may also be more common, although this association is less certain. White blood cell counts are often normal [<a href="#rid33">33,74</a>].</p><p>For most patients, the course is mild and recovery is full, even in the absence of antibiotic therapy. For some, constitutional symptoms can linger for one to two weeks following resolution of respiratory illness, making the total course of illness about one month [<a href="#rid41">41</a>]. Rarely, fulminant cases resulting in respiratory failure and death have been reported, particularly in young, previously healthy individuals [<a href="#rid39">39,52,75-78</a>].</p><p class="headingAnchor" id="H821396909"><span class="h3">Association with asthma</span><span class="headingEndMark"> — </span><em>M. pneumoniae</em> infection may worsen asthma symptoms in children, adolescents, and adults and can also produce wheezing in children who do not have asthma. A separate question, for which there has been some experimental and clinical evidence, is whether <em>M. pneumoniae</em> plays a role in the pathogenesis of asthma. This is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/572.html" rel="external">"Risk factors for asthma", section on 'Respiratory infections'</a>.)</p><p class="headingAnchor" id="H8"><span class="h2">Non-respiratory tract disease</span><span class="headingEndMark"> — </span>Manifestations outside the respiratory tract can occur with or independently of respiratory tract disease. While a wide array of disorders have been associated with <em>M. pneumoniae </em>infection, only a few have an established causal relationship. These include hemolysis, central nervous system (CNS) disease, dermatitis, carditis, joint disease, and gastrointestinal disease.</p><p class="headingAnchor" id="H9"><span class="h3">Hemolysis</span><span class="headingEndMark"> — </span>Hemolysis accompanies <em>M. pneumoniae </em>infection in about 60 percent of cases and is typically mild or subclinical [<a href="#rid21">21</a>]. During the course of infection, <em>Mycoplasma</em> induces an alteration in the I antigen on the erythrocytes membrane. This, in turn, leads to the development of an IgM autoantibody directed at this antigen and immune-mediated hemolysis (also termed cold agglutinin disease) [<a href="#rid79">79</a>]. <em>M. pneumoniae</em> organisms have been shown to elaborate hydrogen sulfide, which may contribute to hemolysis [<a href="#rid80">80</a>]. (See  <a class="medical medical_review" href="/d/html/7084.html" rel="external">"Cold agglutinin disease", section on 'Pathogenesis'</a>.)</p><p>For most patients, hemolysis is self-limited; neither transfusion nor immunosuppressive treatment is needed. Rarely, hemolysis can be severe and life-threatening, particularly in patients with underlying hematologic disorders such as sickle cell disease [<a href="#rid21">21,81,82</a>]. (See  <a class="medical medical_review" href="/d/html/7084.html" rel="external">"Cold agglutinin disease", section on 'Management'</a>.)</p><p class="headingAnchor" id="H3019025176"><span class="h3">CNS involvement</span><span class="headingEndMark"> — </span>Central nervous system (CNS) manifestations occur in approximately 0.1 percent of all patients with <em>M. pneumoniae</em> infections and in up to 7 percent of those patients requiring hospitalization [<a href="#rid72">72,83,84</a>]. Overall, CNS involvement occurs more frequently in children than in adults. In cases of CNS involvement due to <em>M. pneumoniae</em>, a history of an antecedent respiratory illness is usually, but not always, found [<a href="#rid85">85</a>].</p><p>Encephalitis is the most common CNS manifestation. Other manifestations include meningitis, peripheral neuropathy, transverse myelitis, acute disseminated encephalomyelitis (ADEM), Guillain-Barré syndrome (GBS), cranial nerve palsies, and cerebellar ataxia [<a href="#rid86">86-89</a>]. Some of these manifestations, such as meningitis, are thought to be due to direct bacterial invasion of the CNS and occur at illness onset [<a href="#rid90">90</a>]. Others such as ADEM and GBS are thought to be postinfectious immune phenomena, caused by cross-reaction of <em>Mycoplasma</em> antibodies with galactocerebroside [<a href="#rid83">83,91,92</a>]. Stroke can also occur following <em>M. pneumoniae </em>infection, most likely due to vascular injury. However, the pathogenesis of CNS disorders has not been fully defined and the boundaries between infectious, vascular, and immune phenomena are not always clear.</p><p>The prognosis varies with the type and extent of CNS involvement but can be poor. As an example, in a review of 61 individuals with neurologic disease attributed to <em>M. pneumoniae</em> found that 5 patients (8 percent) died and 14 (23 percent) had severe sequelae [<a href="#rid83">83</a>]. Among CNS disorders, transverse myelitis and ADEM can be particularly morbid. In one literature review, 59 percent of patients presenting with spinal cord involvement suffered permanent neurologic sequelae [<a href="#rid93">93</a>].</p><p class="headingAnchor" id="H10"><span class="h3">Mucocutaneous disease</span><span class="headingEndMark"> — </span>Mucocutaneous and cutaneous disease are among the more common non-respiratory tract manifestations of <em>M. pneumoniae</em> infection. Manifestations include mild erythematous maculopapular or vesicular rashes, urticaria, erythema multiforme, Stevens-Johnson syndrome (SJS), and reactive infectious mucocutaneous eruption (RIME, formerly known as <em>M. pneumoniae</em>-induced rash and mucositis [MIRM]) [<a href="#rid94">94-98</a>] (see  <a class="medical medical_review" href="/d/html/120346.html" rel="external">"Reactive infectious mucocutaneous eruption (RIME)"</a>). Concurrent or antecedent respiratory symptoms are often present but not always prominent.</p><p>Like other nonrespiratory tract manifestations, some cutaneous manifestations may result directly from bacterial infection while others may be immune phenomena. Rashes or exanthema are often mild and self-limiting. They are reported to accompany approximately 17 percent of respiratory tract infections and can be confused with hypersensitivity reactions to antibiotics [<a href="#rid90">90</a>].</p><p>Erythema multiforme caused by <em>M. pneumoniae</em> is similar to other forms of this syndrome but more frequently occurs with mucosal and respiratory tract involvement [<a href="#rid98">98</a>]. While SJS is an uncommon manifestation of <em>M. pneumoniae </em>infection, <em>M. pneumoniae</em> appears to be among the most common infectious causes of SJS [<a href="#rid94">94</a>]. Among patients with SJS due to <em>M. pneumoniae</em>, concurrent pneumonia is more common than mild upper respiratory tract infection [<a href="#rid99">99</a>]. (See  <a class="medical medical_review" href="/d/html/5559.html" rel="external">"Erythema multiforme: Pathogenesis, clinical features, and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/2091.html" rel="external">"Stevens-Johnson syndrome and toxic epidermal necrolysis: Pathogenesis, clinical manifestations, and diagnosis"</a>.)</p><p><em>M. pneumoniae</em>-associated mucositis is a syndrome characterized by erosive oral, ocular, and genital lesions that occurs most often in children. (See  <a class="medical medical_review" href="/d/html/6070.html" rel="external">"<i>Mycoplasma pneumoniae</i> infection in children", section on 'Mucocutaneous disease'</a>.)</p><p class="headingAnchor" id="H542358074"><span class="h3">Cardiac involvement</span><span class="headingEndMark"> — </span>Cardiac involvement is a less common non-respiratory tract manifestation of <em>M. pneumoniae</em> infection. The range of reported manifestations include pericarditis, myocarditis, cardiac thrombi, and conduction abnormalities [<a href="#rid52">52,100-104</a>]. There is a single but convincing report of <em>M. pneumoniae</em> endocarditis [<a href="#rid101">101</a>]. There is a putative associated with <em>M. pneumoniae</em> infection and atherosclerotic heart disease based on the seroprevalence of infection in people with atherosclerosis and the detection of <em>M. pneumoniae </em>nucleic acid in atheroma [<a href="#rid105">105</a>]. </p><p>While most cardiac manifestations are thought to be due to direct bacterial infection, some cases of myocarditis and cardiac thrombosis may be immune related [<a href="#rid103">103</a>]. More so than other nonrespiratory tract manifestations, cardiac manifestations tend to occur independently of respiratory tract disease.</p><p class="headingAnchor" id="H542358111"><span class="h3">Other associations</span><span class="headingEndMark"> — </span>Hepatitis, typically manifested as mild elevations in hepatic transaminases, is commonly reported among patients with <em>M. pneumoniae </em>infections [<a href="#rid106">106,107</a>]. Other gastrointestinal complaints tend to be mild and nonspecific.</p><p>Common musculoskeletal manifestations include arthralgias and myalgias; actual arthritis is rare [<a href="#rid78">78,108</a>]. Most cases of <em>M. pneumoniae</em> arthritis are believed to be immune mediated. However, <em>M. pneumoniae</em> has been isolated from synovial fluid in some patients with polyarthritis, suggesting that direct infection is also possible [<a href="#rid109">109</a>].</p><p>A wide variety of other conditions have been associated with <em>M. pneumoniae</em> infection in the medical literature, ranging from anterior uveitis [<a href="#rid110">110-112</a>], glomerulonephritis [<a href="#rid113">113,114</a>], pancreatitis [<a href="#rid21">21</a>], thrombotic microangiopathies [<a href="#rid115">115,116</a>], and rhabdomyolysis [<a href="#rid117">117,118</a>]. Because of the challenges in accurately diagnosing <em>M. pneumoniae </em>infection and the infrequent occurrence of these conditions, the extent to which <em>M. pneumoniae</em> plays a causal role in their pathogenesis is uncertain.</p><p>Previously, <em>M. pneumoniae</em> was believed to cause bullous myringitis [<a href="#rid119">119</a>]. However, accumulating microbiologic and epidemiologic data suggest that this association is spurious [<a href="#rid120">120</a>].</p><p class="headingAnchor" id="H848918678"><span class="h2">COVID-19 coinfection</span><span class="headingEndMark"> — </span>Probable coinfection with coronavirus disease 2019 (COVID-19) and <em>M. pneumoniae</em> has been reported [<a href="#rid121">121</a>]. In one study, patients with COVID-19 who were believed to have concurrent<em> M. pneumoniae</em> infection, had more persistent cough, slightly longer hospitalization, and a longer recovery period than those without evidence of mycoplasma disease [<a href="#rid121">121</a>]. These patients also had higher bilirubin levels and more severe hypercoagulability and thrombosis. Mortality in this study was minimal in both groups. However, signs and symptoms of COVID-19 and <em>M. pneumoniae </em>infection overlap, it is difficult to parse which clinical factors were associated with which pathogen and whether they are additive. (See  <a class="medical medical_review" href="/d/html/128323.html" rel="external">"COVID-19: Clinical features"</a>.) .</p><p class="headingAnchor" id="H16"><span class="h1">DIAGNOSIS</span></p><p class="headingAnchor" id="H1794558583"><span class="h2">URI and acute bronchitis</span><span class="headingEndMark"> — </span>In general, the diagnosis of upper respiratory tract infection (URI) and acute bronchitis are made clinically; we do not pursue a microbiologic diagnosis in patients with mild infections that are expected to improve without treatment, such as URIs and acute bronchitis. (See  <a class="medical medical_review" href="/d/html/6865.html" rel="external">"The common cold in adults: Diagnosis and clinical features"</a> and  <a class="medical medical_review" href="/d/html/6870.html" rel="external">"Acute bronchitis in adults", section on 'Clinical features'</a>.)</p><p class="headingAnchor" id="H3017489716"><span class="h2">Pneumonia</span></p><p class="headingAnchor" id="H1440647531"><span class="h3">Approach to diagnosis</span><span class="headingEndMark"> — </span>For most adults with community-acquired pneumonia (CAP), pursuing a microbiologic diagnosis of <em>M. pneumoniae</em> is not necessary, as results would not change management [<a href="#rid122">122</a>]. Treatment for CAP is typically empiric, and most recommended regimens for adults in the United States include an agent that targets atypical pathogens, such as <em>M. pneumoniae</em> [<a href="#rid122">122</a>]. Most available diagnostic assays for <em>M. pneumoniae</em> have limitations including lack of validation, variable specificity, limited availability, and/or long turnaround times [<a href="#rid123">123</a>].</p><p>We therefore typically reserve <em>M. pneumoniae</em> testing for selected patients with suggestive clinical features or severe pneumonia in whom directing antibiotic therapy at <em>M. pneumoniae</em> would provide benefit (eg, narrowing an otherwise broad empiric regimen) or when having a specific diagnosis would provide prognostic value. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>For patients with a compelling clinical presentation (eg, indolent onset pneumonia with concurrent hemolysis or mucocutaneous disease), we generally obtain a <em>Mycoplasma </em>polymerase chain reaction (PCR) from a respiratory tract sample (eg, nasopharyngeal swab, sputum, bronchoalveolar lavage fluid) to help direct therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with severe CAP, we sometimes obtain a multiplex PCR-based assay that includes testing for <em>M. pneumoniae </em>from an upper or lower respiratory tract sample when pursuing a broad microbiologic evaluation. (See <a class="local">'Molecular testing'</a> below and  <a class="medical medical_review" href="/d/html/7032.html" rel="external">"Clinical evaluation and diagnostic testing for community-acquired pneumonia in adults", section on 'Differential diagnosis'</a>.)</p><p></p><p>During outbreaks, testing (often under the direction of public health authorities) is prudent to help define the nature and duration of the outbreak.</p><p>As the availability of molecular diagnostics increases and turnaround times fall, indications for testing for and subsequently providing pathogen-directed therapy are expected to expand. Presently, some clinicians and experts with multiplex PCR panels or nucleic acid-based tests available at their institutions perform this test on most hospitalized patients with CAP and target therapy at <em>M. pneumoniae</em> when this organism is detected and typical pyogenic bacteria have been ruled out.</p><p>Although PCR-based assays are the tests of choice for diagnosing <em>M. pneumoniae</em> pneumonia, caution is needed when interpreting results. Both asymptomatic carriage and coinfection with <em>M. pneumoniae</em> and other pathogens is relatively common [<a href="#rid22">22,41,124</a>]. PCR-based assays cannot distinguish between active infection caused by <em>M. pneumoniae</em> alone and either asymptomatic carriage or coinfection. Thus, we generally consider positive test results to provide presumptive diagnoses and consider the completeness of the microbiologic evaluation and the clinical context heavily when interpreting results.</p><p>Because these assays are not available at all institutions and turnaround times can be long sending tests to reference laboratories, we also consider the likelihood of obtaining a timely result when deciding to test. Serology using enzyme immunoassay of paired acute and convalescent sera has traditionally been the mainstay of laboratory diagnosis. However, serology is now used as an alternative when a PCR-based assay is not available or as an adjunct to PCR [<a href="#rid123">123</a>]. (See <a class="local">'Mycoplasma-specific assays'</a> below.)</p><p class="headingAnchor" id="H2292627586"><span class="h3">Laboratory studies</span><span class="headingEndMark"> — </span>Hemolysis is the most distinctive laboratory finding associated with <em>M. pneumoniae</em> infection and is typically manifest as a reduction in hemoglobin levels with concurrent rises in unconjugated bilirubin, lactate dehydrogenase, and reticulocyte count [<a href="#rid78">78</a>]. Because the hemolysis is immune mediated (driven by <em>M. pneumoniae</em>-induced cold agglutinins, which target the I antigen on the red blood cell), a direct Coombs test and cold-agglutinin titers are typically positive [<a href="#rid125">125</a>]. While these tests support the diagnosis of <em>M. pneumoniae</em> infection, we do not routinely obtain them as part of our evaluation because <em>M. pneumoniae</em>-associated hemolysis is typically mild and self-limited. Occasionally, cold agglutinins can be used to support a clinical diagnosis of <em>M. pneumoniae</em> infection when a rapid diagnosis must be made. More often, these tests are obtained as part of the evaluation for hemolytic anemia of uncertain cause. (See  <a class="medical medical_review" href="/d/html/7076.html" rel="external">"Diagnosis of hemolytic anemia in adults"</a>.)</p><p>Other laboratory features that support the diagnosis of <em>M. pneumoniae</em> infection are nonspecific but include mildly elevated hepatic transaminases and a normal or mildly elevated white blood cell count. One retrospective study found that a high ratio of serum C-reactive protein to procalcitonin is a strong predictor of <em>M. pneumoniae</em> infection in patients with CAP [<a href="#rid126">126</a>]. However, additional study is needed to help determine whether these results can be used to help guide therapy. </p><p class="headingAnchor" id="H1746984223"><span class="h3">Chest radiograph</span><span class="headingEndMark"> — </span>The radiographic features of <em>M. pneumoniae </em>pneumonia are generally similar to those seen with other atypical or viral pneumonias. The most common radiographic findings on chest radiograph are reticulonodular and/or patchy opacities, which can be unilateral or bilateral  (<a class="graphic graphic_diagnosticimage graphicRef51752" href="/d/graphic/51752.html" rel="external">image 1</a>) [<a href="#rid127">127</a>]. Other findings may include a thickened bronchial shadow, streaks of interstitial infiltrates, and areas of atelectasis. Nodular infiltrates and hilar adenopathy are less common [<a href="#rid41">41,127</a>]. Small pleural effusions, usually unilateral, may be seen in 15 to 20 percent of cases; empyema is rare. Computed tomography (CT) scanning is typically not indicated for patients with CAP, but reported findings among patients with <em>M. pneumoniae</em> pneumonia include centrilobular nodular and tree-in-bud opacities in a patchy distribution, lobular or segmental ground-glass opacities or consolidation, and thickening of the bronchovascular bundle [<a href="#rid127">127-129</a>]. In one study using high-resolution CT to evaluate patients with bacterial CAP, lateral bronchial wall thickening coupled with minimal air bronchograms were indicative of <em>M. pneumoniae</em> pneumonia [<a href="#rid130">130</a>]. Although these radiographic features have been reported among patients with <em>M. pneumoniae</em> pneumonia, they are ultimately not specific enough to distinguish definitively <em>M. pneumoniae</em> pneumonia from other interstitial pneumonias.</p><p class="headingAnchor" id="H62366244"><span class="h2">Mycoplasma-specific assays</span></p><p class="headingAnchor" id="H3915566668"><span class="h3">Molecular testing</span><span class="headingEndMark"> — </span>Nucleic acid amplification tests (NAATs) are the diagnostic method of choice for <em>M. pneumoniae</em> pneumonia. Available assays include direct DNA amplification tests, such as PCR (which detect <em>M. pneumoniae</em> DNA only) and multiplex assays (which detect multiple respiratory tract pathogens on a single sample).</p><p class="bulletIndent1"><span class="glyph">●</span>We generally use direct PCR or other NAAT when our clinical suspicion for <em>M. pneumoniae </em>pneumonia is high (eg, for patients with indolent onset pneumonia and concurrent hemolysis or mucocutaneous disease). NAATs can be performed on most respiratory tract specimen types, including nasopharyngeal swabs, sputum, and bronchoalveolar lavage (BAL) fluid. Direct NAATs can also be performed on other sample types (eg, cardiac tissue, joint fluid, or oral lesions) and thus can be helpful in diagnosing non-respiratory tract infections [<a href="#rid52">52,100,108,109,131</a>]. In the United States, the Illumigene Direct DNA Amplification assay is approved for the diagnosis of <em>M. pneumoniae </em>infections. Assays that concurrently detect macrolide resistance are in development [<a href="#rid132">132-135</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Multiplex PCR-based assays are increasingly being used for the diagnosis of respiratory tract infections [<a href="#rid136">136</a>]. In the United States, the Biofire FilmArray respiratory panel includes <em>M. pneumoniae </em>and has been US Food and Drug Administration (FDA) approved for the diagnosis of respiratory tract infections [<a href="#rid137">137,138</a>]. While the assay is approved for use on nasopharyngeal swabs, it has also been used on sputum and BAL fluid with comparable results [<a href="#rid139">139</a>].</p><p></p><p class="bulletIndent1">For patients with severe pneumonia in whom we are pursuing a broad microbiologic evaluation, we sometimes send multiplex PCR assays on respiratory tract specimens. Although multiplex PCR has been FDA cleared only for use on nasopharyngeal samples, PCR has also been evaluated using other respiratory tract specimens such as throat swabs, sputum, and BAL fluid with varying results [<a href="#rid123">123,140</a>]. In summary, a number of NAAT have been developed. These may be available as part of multiplex assay with variable sensitivities for <em>M. pneumoniae,</em> or as uniplex assay platforms, which may have higher sensitivity. Newer tests use methods other than PCR to detect <em>M. pneumoniae</em> genetic material. In practical terms, the practitioner will be bound by the preference of a given laboratory for one type of test over another [<a href="#rid141">141,142</a>]. </p><p></p><p>Under optimal study conditions, NAATs have high sensitivity and specificity when compared with serology or culture [<a href="#rid138">138,143-145</a>], but caution is needed in interpreting results. NAATs cannot distinguish between active infection and either coinfection with other pathogens or asymptomatic carriage. In addition, the sensitivity of the assay likely varies with the timing of collection in the disease course [<a href="#rid23">23,146</a>]. As an example, in one study that reviewed the performance characteristics of real-time PCR in outbreak settings, the overall sensitivity of real-time PCR was 40 percent sensitivity compared with 40 and 35 percent for the IgM and IgG/IgM assays [<a href="#rid147">147</a>]. The sensitivity of PCR declined with time from 48 percent during the first 21 days of illness to 29 percent at days 22 to 59 days and 12 percent ≥60 days following symptom onset. Specificity of real-time PCR was 98 percent. In another study, PCR of specimens obtained from pharyngeal swabs was more likely to be positive than serology during the early phases of infection, but, for patients presenting during the third week of illness, PCR and serology were equivalent [<a href="#rid23">23</a>]. These studies suggest that PCR (particularly real-time PCR) is most useful during acute illness, when the bacterial burden is high. A test combining loop-mediated isothermal amplification (LAMP) with nanoparticle-based lateral flow biosensor (LAMP-LFR) and targeted at the community-acquired respiratory distress syndrome toxin appears to have high sensitivity and specificity [<a href="#rid148">148</a>].</p><p class="headingAnchor" id="H18"><span class="h3">Serology</span><span class="headingEndMark"> — </span>Serology can be used as an alternative to molecular testing (when not available) or as an adjunct to molecular testing [<a href="#rid146">146</a>].</p><p>As with other infections, the gold standard for serologic diagnosis requires detection of a fourfold rise in IgG titers when comparing acute and convalescent serum samples [<a href="#rid149">149</a>]. Because this requires obtaining serologies both during acute infection and during recovery (approximately four weeks later), this is generally impractical. If the disease is encountered late in its course, a fourfold fall in titer may be as useful as a fourfold rise, although this approach is not well validated. Because IgM titers rise earlier than IgG titers (approximately seven to nine days into illness), using a single high IgM titer to make a presumptive diagnosis is an alternate strategy. However, the specificity of this diagnostic approach is likely low [<a href="#rid150">150</a>]. When molecular testing is also available, a single positive IgM in combination with a positive NAAT result helps corroborate the diagnosis.</p><p>When obtaining serologic testing, enzyme immunoassays are preferred over complement fixation tests due to their higher specificity. Performance characteristics of these assays may also vary considerably among laboratories [<a href="#rid150">150,151</a>].</p><p class="headingAnchor" id="H2122410611"><span class="h3">Culture and other assays</span><span class="headingEndMark"> — </span>Gram stain and culture are generally not helpful for the diagnosis of <em>M. pneumoniae</em> pneumonia. Because the organism lacks a cell wall, it is not visible on Gram stain. Culture is possible but requires specialized media. In addition, <em>M. pneumoniae</em> is a fastidious organism and takes approximately two to three weeks to grow. Thus, most clinical laboratories do not attempt to culture this organism. (See <a class="local">'Microbiology'</a> above.)</p><p>Antigen detection tests are available but have been largely replaced by NAATs [<a href="#rid149">149</a>].</p><p class="headingAnchor" id="H3627326942"><span class="h2">Non-respiratory tract disease</span><span class="headingEndMark"> — </span>The diagnostic approach for <em>M. pneumoniae</em> manifestations that occur outside of the respiratory tract varies with the suspected site of infection, presence of concurrent respiratory tract disease, and whether the manifestation is believed to be immune mediated or a direct result of bacterial infection. We generally pursue diagnosis when the testing results are likely to change management or provide helpful prognostic information.</p><p>When the manifestation is thought to be due to direct infection, diagnosis can be made by detecting or isolating <em>M. pneumoniae</em> at the affected site. When the manifestation is believed to be immune related and/or if direct detection is unrevealing, acute and convalescent serologies are the primary means of making a microbiologic diagnosis. When current respiratory tract disease is present, the diagnosis manifestation is often made presumptively based on detection of <em>M. pneumoniae </em>in the respiratory tract.</p><p>Because the boundaries between direct bacterial infection and immune-mediated processes are not always clear and because available diagnostics have limitations, we generally individualize our approach to diagnosis, keeping the above parameters in mind. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>Hemolysis typically co-occurs with respiratory tract disease and is mild or subclinical. Thus, diagnosis is most often made presumptively based on the presence of hemolytic anemia in a patient with known <em>M. pneumoniae</em> respiratory tract disease.</p><p></p><p class="bulletIndent1">Rarely, hemolysis is severe and is the dominant presenting sign of infection. In this scenario, a positive direct Coombs test and/or cold-agglutinin titer can help corroborate the diagnosis of <em>M. pneumoniae </em>infection [<a href="#rid152">152</a>]. Acute or convalescent serologies and/or detection of <em>M. pneumoniae</em> in the respiratory tract (if respiratory symptoms are present) can help confirm the diagnosis [<a href="#rid82">82</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with neurologic involvement, cerebrospinal fluid (CSF) typically reveals a lymphocytic pleocytosis, elevated protein, and normal glucose [<a href="#rid84">84</a>]. If the manifestation is thought to be due to direct bacterial invasion of the CNS (eg, meningitis), PCR or culture can be used to detect <em>M. pneumoniae</em> in the CSF. However, the diagnostic yield of this approach is uncertain [<a href="#rid83">83,84,93</a>]. <em>Mycoplasma</em>-specific serologies from peripheral blood and from the CSF can also be used to help make microbiologic diagnosis; however, their sensitivity and specificity are also uncertain. (See  <a class="medical medical_review" href="/d/html/1278.html" rel="external">"Molecular diagnosis of central nervous system infections"</a>.)</p><p></p><p>For other non-respiratory tract manifestations such as carditis, arthritis, and mucocutaneous disease, diagnosis can sometimes be made by detection of <em>M. pneumoniae</em> at the affected site by PCR (eg, from myocardial tissue, synovial fluid, oral lesions, or vesicular fluid) [<a href="#rid52">52,100,108,109,131</a>].</p><p class="headingAnchor" id="H22"><span class="h1">TREATMENT</span></p><p class="headingAnchor" id="H2856294782"><span class="h2">Pneumonia</span></p><p class="headingAnchor" id="H265731888"><span class="h3">Empiric therapy</span><span class="headingEndMark"> — </span>For most patients with community-acquired pneumonia (CAP), the etiology is not known at the time of diagnosis, and empiric treatment is appropriate. In the United States, most recommended empiric regimens include an agent that targets both "typical" pathogens (eg, <em>Streptococcus pneumoniae</em>) as well as atypical pathogens, such as <em>M. pneumoniae</em> [<a href="#rid122">122</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>For outpatients, empiric regimens generally include a macrolide (eg, <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a>), <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a>, or a respiratory fluoroquinolone (eg, <a class="drug drug_general" data-topicid="9554" href="/d/drug information/9554.html" rel="external">levofloxacin</a> or <a class="drug drug_general" data-topicid="10311" href="/d/drug information/10311.html" rel="external">moxifloxacin</a>). Each of these agents is active against <em>M. pneumoniae</em>,<em> </em>although there is regional resistance to macrolides  (<a class="graphic graphic_algorithm graphicRef111829" href="/d/graphic/111829.html" rel="external">algorithm 1</a>)<em> </em>(see <a class="local">'Macrolide resistance'</a> below).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For hospitalized patients not requiring intensive care unit (ICU) admission, treatment with either a respiratory fluoroquinolone or treatment with a beta-lactam (eg, <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a> or <a class="drug drug_general" data-topicid="9221" href="/d/drug information/9221.html" rel="external">cefotaxime</a>) plus a macrolide are first-line options for most patients  (<a class="graphic graphic_algorithm graphicRef112543" href="/d/graphic/112543.html" rel="external">algorithm 2</a>).</p><p></p><p>Although <em>M. pneumoniae</em> pneumonia is rarely severe enough to require ICU admission, most recommended empiric regimens for patients admitted to the ICU with CAP include either a respiratory fluoroquinolone or a macrolide  (<a class="graphic graphic_algorithm graphicRef112544" href="/d/graphic/112544.html" rel="external">algorithm 3</a>). Modifications to these regimens may be needed based on severity of illness, patient comorbidities and drug intolerances, local epidemiology, and risk factors for multidrug-resistant organisms. Antibiotic selection and duration of therapy vary with treatment setting and are discussed separately. (See  <a class="medical medical_review" href="/d/html/7031.html" rel="external">"Treatment of community-acquired pneumonia in adults in the outpatient setting"</a> and  <a class="medical medical_review" href="/d/html/7027.html" rel="external">"Treatment of community-acquired pneumonia in adults who require hospitalization"</a>.)</p><p class="headingAnchor" id="H1918355005"><span class="h3">Mycoplasma-specific therapy</span><span class="headingEndMark"> — </span>For patients with microbiologically confirmed <em>M. pneumoniae</em> pneumonia, first-line treatment options include macrolides (eg, <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a>), tetracyclines (eg, <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a>), and respiratory fluoroquinolones (eg, <a class="drug drug_general" data-topicid="9554" href="/d/drug information/9554.html" rel="external">levofloxacin</a> or <a class="drug drug_general" data-topicid="10311" href="/d/drug information/10311.html" rel="external">moxifloxacin</a>).</p><p>We generally select among these agents based on patient comorbidities, potential drug interactions, and the likelihood of macrolide resistance. (See <a class="local">'Macrolide resistance'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span>For most patients with <em>M. pneumoniae</em> pneumonia in regions where macrolide resistance is low (ie, &lt;20 percent), such as the United States, we use <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> (either 500 mg orally on day 1 followed by 250 mg orally for four additional days or 500 mg orally for three days).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>When macrolide resistance is suspected based on local epidemiology (eg, in most of Asia and some parts of Europe) or other factors, we recommend either <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> (100 mg orally twice daily) or a respiratory fluoroquinolone (<a class="drug drug_general" data-topicid="9554" href="/d/drug information/9554.html" rel="external">levofloxacin</a> 500 mg orally daily or <a class="drug drug_general" data-topicid="10311" href="/d/drug information/10311.html" rel="external">moxifloxacin</a> 400 mg orally once daily).</p><p></p><p class="bulletIndent1">When using an antibiotic other than <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> (which has a prolonged half-life), we base treatment duration on the patient's clinical response. For most patients with <em>M. pneumoniae</em> pneumonia, infection is mild and a five- to seven-day treatment course is sufficient. In more severe cases, 7 to 14 days may be needed. In all cases, we ensure that the patient is afebrile, clinically stable, and improving before stopping antibiotics.</p><p></p><p>Among antibiotics with activity against <em>M. pneumoniae</em>, <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> is the least likely to develop resistance based on in vitro studies [<a href="#rid153">153,154</a>]. Azithromycin's side effect profile is also generally favorable; by contrast, because of their higher side effect profile fluoroquinolones are often avoided in patients with mild disease and in younger patients. Clinical trial data are limited but do support azithromycin's high efficacy [<a href="#rid155">155</a>]. <a class="drug drug_general" data-topicid="9554" href="/d/drug information/9554.html" rel="external">Levofloxacin</a> and <a class="drug drug_general" data-topicid="10311" href="/d/drug information/10311.html" rel="external">moxifloxacin</a> also appear to be effective based on clinical trial data; however, the number of patients with <em>M. pneumoniae</em> infection in these trials is small [<a href="#rid156">156,157</a>]. Tetracyclines have been most well studied in children and also appear to be effective [<a href="#rid158">158</a>]. Beta-lactams such as penicillin and other antibiotics that target cell wall synthesis are ineffective because <em>Mycoplasma </em>species do not have a cell wall [<a href="#rid159">159</a>].</p><p>While our preference is to determine treatment duration based on clinical response, the optimal length of therapy for <em>M. pneumoniae</em> infection is not established. Because the organism can cause persistent infection, shedding can be prolonged, and clinical relapse has been reported [<a href="#rid22">22,23,160</a>], our threshold to extend the treatment course (eg, 7 to 14 days) is low. This is particularly true for immunocompromised patients and those with delayed resolution and/or chronic comorbidities. Patients with non-respiratory tract disease may also require longer courses of treatment. (See <a class="local">'Non-respiratory tract disease'</a> below.)</p><p class="headingAnchor" id="H448358914"><span class="h2">Non-respiratory tract disease</span><span class="headingEndMark"> — </span>Antibiotic therapy is the mainstay of treatment for non-respiratory tract <em>M. pneumoniae</em> disease. When selecting an antibiotic for the treatment of <em>M. pneumoniae</em> infections outside of the lung, we generally select among active agents (ie, <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a>, fluoroquinolones, and tetracyclines) based on patient age, the degree to which the agent penetrates the site of infection, and the likelihood of drug resistance. (See <a class="local">'Macrolide resistance'</a> below.)</p><p>Because some forms of manifestations of <em>M. pneumoniae </em>infection that occur outside the respiratory tract may be immune mediated rather than directly caused by bacterial infection, use of immunosuppressive agents or immunomodulatory therapy may be warranted for some patients. We generally individualize the decision to use these adjunctive therapies based on the site of infection, severity of illness, and clinical suspicion for an active immune-mediated process (eg, Guillain-Barré syndrome, acute demyelinating encephalomyelitis, severe hemolysis).</p><p>As examples, glucocorticoids, plasmapheresis, and intravenous <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">immune globulin</a> have each been used in addition to antibiotics for the treatment of central nervous system diseases [<a href="#rid84">84,161,162</a>]. Although most cases of <em>M. pneumoniae</em>-related hemolysis are mild or subclinical and self-limited, for severe cases of hemolytic anemia, warming, glucocorticoids, and plasmapheresis have been reported to help [<a href="#rid8">8,114,163</a>].</p><p class="headingAnchor" id="H2945259158"><span class="h2">Macrolide resistance</span><span class="headingEndMark"> — </span>When selecting an antibiotic for the treatment of known or suspected <em>M. pneumoniae</em> infection, it is important to take the likelihood of macrolide resistance into account. Macrolide resistance has been increasing in frequency in various regions worldwide, particularly in Asia [<a href="#rid164">164</a>]. In a surveillance study from Japan from 2008 to 2013, 50 to 93 percent of isolates from children were resistant to macrolides, and the incidence of macrolide resistance increased over the time period assessed in the study [<a href="#rid165">165</a>]. In a report from China, 95 percent of <em>M. pneumoniae</em> isolates from adult patients with respiratory tract infections were resistant to macrolides [<a href="#rid166">166</a>]. Macrolide resistance has also been reported in 5 to 13 percent of isolates studied in France and the United States, with the highest regional rates reported in the eastern and southern United States [<a href="#rid46">46,167-170</a>]. Resistance in the United States from 2014 to 2021 averaged 10 percent [<a href="#rid171">171</a>]. Although a significant proportion of isolates worldwide remain susceptible to macrolides, alternative therapy should be considered in patients with severe or refractory disease, particularly in those who reside in areas with higher macrolide resistance rates. Macrolide resistance is not uniformly nor frequently measured in geographic areas where it has not been high. Macrolide resistance tests using NAAT methodology have been developed and are expected to lead to increased testing [<a href="#rid141">141</a>]. <a class="drug drug_general" data-topicid="122343" href="/d/drug information/122343.html" rel="external">Lefamulin</a>, a pleuromutilin, has in vitro efficacy against <em>M. pneumoniae</em> and might be a potential alterative when macrolide resistance is known or suspected and other agents cannot be used [<a href="#rid172">172</a>]; <a class="drug drug_general" data-topicid="9458" href="/d/drug information/9458.html" rel="external">tigecycline</a> proved therapeutic in a single case report [<a href="#rid173">173</a>].</p><p class="headingAnchor" id="H26"><span class="h1">PREVENTION</span><span class="headingEndMark"> — </span>Because <em>M. pneumoniae</em> is spread from person to person primarily via respiratory droplets, hand and respiratory hygiene as well as isolation of hospitalized patients are important for preventing spread.</p><p class="headingAnchor" id="H1804650166"><span class="h2">Infection control</span><span class="headingEndMark"> — </span>Hospitalized patients with pneumonia caused by <em>Mycoplasma</em> species should be placed on droplet precautions, which should continue for the duration of the illness [<a href="#rid174">174</a>]. (See  <a class="medical medical_review" href="/d/html/4042.html" rel="external">"Infection prevention: Precautions for preventing transmission of infection", section on 'Droplet precautions'</a>.)</p><p>Reminding all patients of the importance of washing their hands with soap and water, using an alcohol-based hand sanitizer, and covering one's mouth when coughing or sneezing may also help prevent spread [<a href="#rid52">52</a>].</p><p class="headingAnchor" id="H4284746196"><span class="h2">Postexposure prophylaxis</span><span class="headingEndMark"> — </span>Antimicrobial prophylaxis is not needed for most patients who have been exposed to a person with an active <em>M. pneumoniae</em> infection. However, during outbreaks in close-contact settings or for selected individual patients (eg, an immunocompromised lung transplant recipient), antimicrobial prophylaxis may be warranted.</p><p>Several studies have evaluated the efficacy of <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> prophylaxis, either during outbreaks of <em>M. pneumoniae</em> pneumonia or in closed settings, such as military training facilities, in which the risk of acquisition is high [<a href="#rid53">53,54,56,175</a>]. As an example, in a randomized trial in 464 military recruits, those receiving azithromycin were less likely to develop respiratory infections than those receiving <a class="drug drug_general" data-topicid="9551" href="/d/drug information/9551.html" rel="external">penicillin G benzathine</a> (risk ratio 0.5, 95% CI 0.28-0.92) [<a href="#rid56">56</a>]. <em>M. pneumoniae</em> infections occurred in 1 of 14 patients receiving azithromycin compared with 6 of 30 receiving penicillin.</p><p class="headingAnchor" id="H2135665338"><span class="h2">Vaccination</span><span class="headingEndMark"> — </span>No vaccine is available for the prevention <em>M. pneumoniae</em> infection; this is due in part to the low efficacy among <em>M. pneumoniae</em> vaccines in development [<a href="#rid70">70</a>].</p><p class="headingAnchor" id="H2338800612"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/104226.html" rel="external">"Society guideline links: Community-acquired pneumonia in adults"</a>.)</p><p class="headingAnchor" id="H28"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Background</strong> − <em>Mycoplasma pneumoniae</em> is among the most common bacterial causes of upper respiratory tract infection (URI), acute bronchitis, and community-acquired pneumonia (CAP) in adults and children. (See <a class="local">'Introduction'</a> above and <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Microbiology</strong> − <em>M. pneumoniae </em>lacks a cell wall and<em> </em>is one of the smallest free-living organisms. Because it lacks a cell wall, it is not visible on Gram stain and is not susceptible to antibiotics that inhibit cell wall synthesis, such as penicillins. These features designate <em>M. pneumoniae</em> as an "atypical" pathogen. (See <a class="local">'Microbiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Transmission</strong> − The organism is transmitted from person to person primarily via respiratory droplets and can cause both sporadic infections and sustained outbreaks. Outbreaks most frequently occur among persons living in close quarters, such as households, schools, and military facilities, but can also spread to the community. (See <a class="local">'Transmission'</a> above and <a class="local">'Outbreaks'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>URI and acute bronchitis</strong> − URI and acute bronchitis are the most common manifestations of <em>M. pneumoniae</em> infection. Clinical features associated with URI and acute bronchitis caused by <em>M. pneumoniae</em> are similar to those caused by other respiratory pathogens. Because these infections are typically mild and self-limited, microbiologic diagnosis and antibiotic treatment is generally unnecessary. (See <a class="local">'URI and acute bronchitis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Community-acquired pneumonia</strong> − Pneumonia caused by <em>M. pneumoniae</em> is typically mild and community acquired. No clinical or radiographic features definitively distinguish <em>M. pneumoniae</em> pneumonia from that caused by other pathogens, although an indolent onset, concurrent URI symptoms (eg, rhinorrhea, pharyngitis, ear ache), and the presence of non-respiratory tract manifestations (eg, hemolysis) are suggestive. (See <a class="local">'Pneumonia'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Extrapulmonary manifestations</strong> − Manifestations outside the respiratory tract can occur with respiratory tract infections or independently. Hemolysis is the most common, and it is typically mild and self-limited. Rarely, <em>M. pneumoniae</em> infection directly infects or triggers immune-mediated reactions in the central nervous system, heart, skin, and other organs. (See <a class="local">'Non-respiratory tract disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis in patients with CAP</strong> − For most patients with CAP, pursuing a microbiologic diagnosis of <em>M. pneumoniae </em>is not necessary, as results would not change management. We typically reserve <em>M. pneumoniae</em> testing for selected patients with suggestive clinical features or severe pneumonia in whom directing antibiotic therapy at <em>M. pneumoniae</em> would provide benefit or when having a specific diagnosis would provide prognostic value. (See <a class="local">'Approach to diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Microbiologic testing</strong> − When microbiologic confirmation is desired for patients with CAP, we use a nucleic acid amplification test (NAAT), such as polymerase chain reaction (PCR). These tests can be performed on most specimen types, including nasopharyngeal swabs, sputum, and bronchoalveolar lavage (BAL) fluid. Because NAATs cannot distinguish between active infection and either coinfection with other pathogens or asymptomatic carriage, clinical judgement should be used in interpreting results. Serology can be used as an alternative or adjunct to NAATs. (See <a class="local">'Mycoplasma-specific assays'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Empiric treatment for patients with CAP</strong> − For most patients with CAP, the etiology is not known at the time of diagnosis, and empiric treatment for CAP is appropriate. Most recommended empiric regimens for adults in the United States include an agent that targets atypical pathogens, such as <em>M. pneumoniae</em>  (<a class="graphic graphic_algorithm graphicRef111829" href="/d/graphic/111829.html" rel="external">algorithm 1</a> and <a class="graphic graphic_algorithm graphicRef112543" href="/d/graphic/112543.html" rel="external">algorithm 2</a>). (See  <a class="medical medical_review" href="/d/html/7027.html" rel="external">"Treatment of community-acquired pneumonia in adults who require hospitalization", section on 'Initial empiric therapy'</a> and  <a class="medical medical_review" href="/d/html/7031.html" rel="external">"Treatment of community-acquired pneumonia in adults in the outpatient setting", section on 'General approach'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Directed treatment of </strong><strong><em>M. pneumonia</em></strong> − For patients with microbiologically confirmed <em>M. pneumoniae</em> pneumonia, first-line treatment options include macrolides (eg, <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a>), tetracyclines (eg, <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a>), and respiratory fluoroquinolones (eg, <a class="drug drug_general" data-topicid="9554" href="/d/drug information/9554.html" rel="external">levofloxacin</a> or <a class="drug drug_general" data-topicid="10311" href="/d/drug information/10311.html" rel="external">moxifloxacin</a>). In regions where macrolide resistance is low, such as the United States, we generally use azithromycin (either 500 mg orally on day 1 followed by 250 mg orally for four additional days or 500 mg orally for three days) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Pneumonia'</a> above and <a class="local">'Macrolide resistance'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis of non-respiratory tract disease</strong> − The approach to diagnosis and treatment of manifestations that occur outside the respiratory tract is typically individualized based on the site of involvement, likelihood of antimicrobial resistance, and presence of concurrent respiratory tract infection. While antibiotic treatment is the mainstay of therapy, some non-respiratory tract manifestations may be immune mediated and adjunctive therapy with glucocorticoids or intravenous <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">immune globulin</a> may be beneficial. (See <a class="local">'Non-respiratory tract disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention</strong> − Key preventive measures include hand hygiene and respiratory hygiene. Postexposure prophylaxis may be indicated in rare and selected circumstances, such as outbreaks or for severely immunocompromised patients. (See <a class="local">'Prevention'</a> above.)</p><p></p><p class="headingAnchor" id="H423073823"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>UpToDate gratefully acknowledges John G Bartlett, MD (deceased), who contributed on earlier versions of this topic and was a founding Editor-in-Chief for UpToDate in Infectious Diseases.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Taylor-Robinson D. Infections due to species of Mycoplasma and Ureaplasma: an update. Clin Infect Dis 1996; 23:671.</a></li><li><a class="nounderline abstract_t">Gillespie SH, Ling CL, Oravcova K, et al. Genomic Investigations unmask Mycoplasma amphoriforme, a new respiratory pathogen. Clin Infect Dis 2015; 60:381.</a></li><li><a class="nounderline abstract_t">van Schaik ML, Patberg KW, Wallinga JG, et al. Mycoplasma amphoriforme vs M. pneumoniae: similarities and differences between patient characteristics in a regional hospital in the Netherlands. J Med Microbiol 2018; 67:1348.</a></li><li><a class="nounderline abstract_t">Baseman JB, Tully JG. Mycoplasmas: sophisticated, reemerging, and burdened by their notoriety. Emerg Infect Dis 1997; 3:21.</a></li><li><a class="nounderline abstract_t">Krause DC, Balish MF. Cellular engineering in a minimal microbe: structure and assembly of the terminal organelle of Mycoplasma pneumoniae. Mol Microbiol 2004; 51:917.</a></li><li><a class="nounderline abstract_t">Page CA, Krause DC. Protein kinase/phosphatase function correlates with gliding motility in Mycoplasma pneumoniae. J Bacteriol 2013; 195:1750.</a></li><li><a class="nounderline abstract_t">Feizi T, Loveless RW. Carbohydrate recognition by Mycoplasma pneumoniae and pathologic consequences. Am J Respir Crit Care Med 1996; 154:S133.</a></li><li><a class="nounderline abstract_t">Baseman JB, Reddy SP, Dallo SF. Interplay between mycoplasma surface proteins, airway cells, and the protean manifestations of mycoplasma-mediated human infections. Am J Respir Crit Care Med 1996; 154:S137.</a></li><li><a class="nounderline abstract_t">Seya T, Matsumoto M. A lipoprotein family from Mycoplasma fermentans confers host immune activation through Toll-like receptor 2. Int J Biochem Cell Biol 2002; 34:901.</a></li><li><a class="nounderline abstract_t">Lührmann A, Deiters U, Skokowa J, et al. In vivo effects of a synthetic 2-kilodalton macrophage-activating lipopeptide of Mycoplasma fermentans after pulmonary application. Infect Immun 2002; 70:3785.</a></li><li><a class="nounderline abstract_t">Yang J, Hooper WC, Phillips DJ, Talkington DF. Cytokines in Mycoplasma pneumoniae infections. Cytokine Growth Factor Rev 2004; 15:157.</a></li><li><a class="nounderline abstract_t">Luo Y, Li C, Zhou Z, et al. Biological functions of IL-17-producing cells in mycoplasma respiratory infection. Immunology 2021; 164:223.</a></li><li><a class="nounderline abstract_t">Yavlovich A, Tarshis M, Rottem S. Internalization and intracellular survival of Mycoplasma pneumoniae by non-phagocytic cells. FEMS Microbiol Lett 2004; 233:241.</a></li><li><a class="nounderline abstract_t">Spuesens EBM, Oduber M, Hoogenboezem T, et al. Sequence variations in RepMP2/3 and RepMP4 elements reveal intragenomic homologous DNA recombination events in Mycoplasma pneumoniae. Microbiology (Reading) 2009; 155:2182.</a></li><li><a class="nounderline abstract_t">Kannan TR, Baseman JB. ADP-ribosylating and vacuolating cytotoxin of Mycoplasma pneumoniae represents unique virulence determinant among bacterial pathogens. Proc Natl Acad Sci U S A 2006; 103:6724.</a></li><li><a class="nounderline abstract_t">Lluch-Senar M, Cozzuto L, Cano J, et al. Comparative "-omics" in Mycoplasma pneumoniae Clinical Isolates Reveals Key Virulence Factors. PLoS One 2015; 10:e0137354.</a></li><li><a class="nounderline abstract_t">Su X, You X, Luo H, et al. Community-Acquired Respiratory Distress Syndrome Toxin: Unique Exotoxin for M. pneumoniae. Front Microbiol 2021; 12:766591.</a></li><li><a class="nounderline abstract_t">Fan Y, Ding Y, Li Y, et al. Investigation of the relationship between community-acquired respiratory distress syndrome toxin and the high-mobility group box protein 1-toll-like receptors-myeloid differentiation factor 88 signaling pathway in Mycoplasma pneumoniae pneumonia. Ital J Pediatr 2022; 48:64.</a></li><li><a class="nounderline abstract_t">Simmons WL, Daubenspeck JM, Osborne JD, et al. Type 1 and type 2 strains of Mycoplasma pneumoniae form different biofilms. Microbiology 2013; 159:737.</a></li><li><a class="nounderline abstract_t">Martin RE, Bates JH. Atypical pneumonia. Infect Dis Clin North Am 1991; 5:585.</a></li><li><a class="nounderline abstract_t">Luby JP. Pneumonia caused by Mycoplasma pneumoniae infection. Clin Chest Med 1991; 12:237.</a></li><li><a class="nounderline abstract_t">Spuesens EB, Fraaij PL, Visser EG, et al. Carriage of Mycoplasma pneumoniae in the upper respiratory tract of symptomatic and asymptomatic children: an observational study. PLoS Med 2013; 10:e1001444.</a></li><li><a class="nounderline abstract_t">Nilsson AC, Björkman P, Persson K. Polymerase chain reaction is superior to serology for the diagnosis of acute Mycoplasma pneumoniae infection and reveals a high rate of persistent infection. BMC Microbiol 2008; 8:93.</a></li><li><a class="nounderline abstract_t">Prince OA, Krunkosky TM, Sheppard ES, Krause DC. Modelling persistent Mycoplasma pneumoniae infection of human airway epithelium. Cell Microbiol 2018; 20.</a></li><li><a class="nounderline abstract_t">de Groot RCA, Estevão SC, Meyer Sauteur PM, et al. Mycoplasma pneumoniae carriage evades induction of protective mucosal antibodies. Eur Respir J 2022; 59.</a></li><li><a class="nounderline abstract_t">Foy HM, Kenny GE, Cooney MK, Allan ID. Long-term epidemiology of infections with Mycoplasma pneumoniae. J Infect Dis 1979; 139:681.</a></li><li><a class="nounderline abstract_t">Hammerschlag MR. Mycoplasma pneumoniae infections. Curr Opin Infect Dis 2001; 14:181.</a></li><li><a class="nounderline abstract_t">Marrie TJ. Mycoplasma pneumoniae pneumonia requiring hospitalization, with emphasis on infection in the elderly. Arch Intern Med 1993; 153:488.</a></li><li><a class="nounderline abstract_t">Falguera M, Sacristán O, Nogués A, et al. Nonsevere community-acquired pneumonia: correlation between cause and severity or comorbidity. Arch Intern Med 2001; 161:1866.</a></li><li><a class="nounderline abstract_t">Garbino J, Sommer R, Gerber A, et al. Prospective epidemiologic survey of patients with community-acquired pneumonia requiring hospitalization in Switzerland. Int J Infect Dis 2002; 6:288.</a></li><li><a class="nounderline abstract_t">Holter JC, Müller F, Bjørang O, et al. Etiology of community-acquired pneumonia and diagnostic yields of microbiological methods: a 3-year prospective study in Norway. BMC Infect Dis 2015; 15:64.</a></li><li><a class="nounderline abstract_t">Johansson N, Kalin M, Tiveljung-Lindell A, et al. Etiology of community-acquired pneumonia: increased microbiological yield with new diagnostic methods. Clin Infect Dis 2010; 50:202.</a></li><li><a class="nounderline abstract_t">Lieberman D, Schlaeffer F, Lieberman D, et al. Mycoplasma pneumoniae community-acquired pneumonia: a review of 101 hospitalized adult patients. Respiration 1996; 63:261.</a></li><li><a class="nounderline abstract_t">Maartens G, Lewis SJ, de Goveia C, et al. 'Atypical' bacteria are a common cause of community-acquired pneumonia in hospitalised adults. S Afr Med J 1994; 84:678.</a></li><li><a class="nounderline abstract_t">Wattanathum A, Chaoprasong C, Nunthapisud P, et al. Community-acquired pneumonia in southeast Asia: the microbial differences between ambulatory and hospitalized patients. Chest 2003; 123:1512.</a></li><li><a class="nounderline abstract_t">Jain S, Self WH, Wunderink RG, et al. Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults. N Engl J Med 2015; 373:415.</a></li><li><a class="nounderline abstract_t">Marrie TJ, Poulin-Costello M, Beecroft MD, Herman-Gnjidic Z. Etiology of community-acquired pneumonia treated in an ambulatory setting. Respir Med 2005; 99:60.</a></li><li><a class="nounderline abstract_t">Bjarnason A, Westin J, Lindh M, et al. Incidence, Etiology, and Outcomes of Community-Acquired Pneumonia: A Population-Based Study. Open Forum Infect Dis 2018; 5:ofy010.</a></li><li class="breakAll">Baum SG. Mycoplasma pneumoniae and atypical pneumonia. In: Principles and Practice of Infectious Diseases, 7th Ed, Mandell GL, Bennett JE, Dolin R (Eds), Churchill Livingstone, Philadelphia 2010. p.2481.</li><li><a class="nounderline abstract_t">Jain S, Williams DJ, Arnold SR, et al. Community-acquired pneumonia requiring hospitalization among U.S. children. N Engl J Med 2015; 372:835.</a></li><li><a class="nounderline abstract_t">Clyde WA Jr. Clinical overview of typical Mycoplasma pneumoniae infections. Clin Infect Dis 1993; 17 Suppl 1:S32.</a></li><li><a class="nounderline abstract_t">Kim EK, Youn YS, Rhim JW, et al. Epidemiological comparison of three Mycoplasma pneumoniae pneumonia epidemics in a single hospital over 10 years. Korean J Pediatr 2015; 58:172.</a></li><li><a class="nounderline abstract_t">Qu J, Yang C, Bao F, et al. Epidemiological characterization of respiratory tract infections caused by Mycoplasma pneumoniae during epidemic and post-epidemic periods in North China, from 2011 to 2016. BMC Infect Dis 2018; 18:335.</a></li><li><a class="nounderline abstract_t">Brown RJ, Nguipdop-Djomo P, Zhao H, et al. Mycoplasma pneumoniae Epidemiology in England and Wales: A National Perspective. Front Microbiol 2016; 7:157.</a></li><li><a class="nounderline abstract_t">Ito I, Ishida T, Osawa M, et al. Culturally verified Mycoplasma pneumoniae pneumonia in Japan: a long-term observation from 1979-99. Epidemiol Infect 2001; 127:365.</a></li><li><a class="nounderline abstract_t">Diaz MH, Benitez AJ, Winchell JM. Investigations of Mycoplasma pneumoniae infections in the United States: trends in molecular typing and macrolide resistance from 2006 to 2013. J Clin Microbiol 2015; 53:124.</a></li><li><a class="nounderline abstract_t">Lind K, Benzon MW, Jensen JS, Clyde WA Jr. A seroepidemiological study of Mycoplasma pneumoniae infections in Denmark over the 50-year period 1946-1995. Eur J Epidemiol 1997; 13:581.</a></li><li><a class="nounderline abstract_t">Miyashita N, Kawai Y, Akaike H, et al. Transmission of macrolide-resistant Mycoplasma pneumoniae within a family. J Infect Chemother 2013; 19:1196.</a></li><li><a class="nounderline abstract_t">Walter ND, Grant GB, Bandy U, et al. Community outbreak of Mycoplasma pneumoniae infection: school-based cluster of neurologic disease associated with household transmission of respiratory illness. J Infect Dis 2008; 198:1365.</a></li><li><a class="nounderline abstract_t">Waller JL, Diaz MH, Petrone BL, et al. Detection and characterization of Mycoplasma pneumoniae during an outbreak of respiratory illness at a university. J Clin Microbiol 2014; 52:849.</a></li><li><a class="nounderline abstract_t">Ralston D, Cochran B. A college epidemic of Mycoplasma pneumoniae. J Am Coll Health Assoc 1979; 27:264, 266.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Mycoplasma pneumoniae outbreak at a university - Georgia, 2012. MMWR Morb Mortal Wkly Rep 2013; 62:603.</a></li><li><a class="nounderline abstract_t">Klausner JD, Passaro D, Rosenberg J, et al. Enhanced control of an outbreak of Mycoplasma pneumoniae pneumonia with azithromycin prophylaxis. J Infect Dis 1998; 177:161.</a></li><li><a class="nounderline abstract_t">Hyde TB, Gilbert M, Schwartz SB, et al. Azithromycin prophylaxis during a hospital outbreak of Mycoplasma pneumoniae pneumonia. J Infect Dis 2001; 183:907.</a></li><li><a class="nounderline abstract_t">Hastings DL, Harrington KJ, Kutty PK, et al. Mycoplasma pneumoniae outbreak in a long-term care facility--Nebraska, 2014. MMWR Morb Mortal Wkly Rep 2015; 64:296.</a></li><li><a class="nounderline abstract_t">Gray GC, Witucki PJ, Gould MT, et al. Randomized, placebo-controlled clinical trial of oral azithromycin prophylaxis against respiratory infections in a high-risk, young adult population. Clin Infect Dis 2001; 33:983.</a></li><li><a class="nounderline abstract_t">Klement E, Talkington DF, Wasserzug O, et al. Identification of risk factors for infection in an outbreak of Mycoplasma pneumoniae respiratory tract disease. Clin Infect Dis 2006; 43:1239.</a></li><li><a class="nounderline abstract_t">Feikin DR, Moroney JF, Talkington DF, et al. An outbreak of acute respiratory disease caused by Mycoplasma pneumoniae and adenovirus at a federal service training academy: new implications from an old scenario. Clin Infect Dis 1999; 29:1545.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Outbreak of community-acquired pneumonia caused by Mycoplasma pneumoniae--Colorado, 2000. MMWR Morb Mortal Wkly Rep 2001; 50:227.</a></li><li><a class="nounderline abstract_t">Nir-Paz R, Abutbul A, Moses AE, et al. Ongoing epidemic of Mycoplasma pneumoniae infection in Jerusalem, Israel, 2010 to 2012. Euro Surveill 2012; 17.</a></li><li><a class="nounderline abstract_t">Beeton ML, Zhang XS, Uldum SA, et al. Mycoplasma pneumoniae infections, 11 countries in Europe and Israel, 2011 to 2016. Euro Surveill 2020; 25.</a></li><li><a class="nounderline abstract_t">Dumke R, Schnee C, Pletz MW, et al. Mycoplasma pneumoniae and Chlamydia spp. infection in community-acquired pneumonia, Germany, 2011-2012. Emerg Infect Dis 2015; 21:426.</a></li><li><a class="nounderline abstract_t">Pereyre S, Touati A, Petitjean-Lecherbonnier J, et al. The increased incidence of Mycoplasma pneumoniae in France in 2011 was polyclonal, mainly involving M. pneumoniae type 1 strains. Clin Microbiol Infect 2013; 19:E212.</a></li><li><a class="nounderline abstract_t">Polkowska A, Harjunpää A, Toikkanen S, et al. Increased incidence of Mycoplasma pneumoniae infection in Finland, 2010-2011. Euro Surveill 2012; 17.</a></li><li><a class="nounderline abstract_t">Chalker V, Stocki T, Litt D, et al. Increased detection of Mycoplasma pneumoniae infection in children in England and Wales, October 2011 to January 2012. Euro Surveill 2012; 17.</a></li><li><a class="nounderline abstract_t">Denny FW, Clyde WA Jr, Glezen WP. Mycoplasma pneumoniae disease: clinical spectrum, pathophysiology, epidemiology, and control. J Infect Dis 1971; 123:74.</a></li><li><a class="nounderline abstract_t">Waites KB, Xiao L, Liu Y, et al. Mycoplasma pneumoniae from the Respiratory Tract and Beyond. Clin Microbiol Rev 2017; 30:747.</a></li><li><a class="nounderline abstract_t">Palma S C, Martínez T MA, Salinas S M, Rojas G P. [Asymptomatic pharyngeal carriage of Mycoplasma pneumoniae in Chilean children]. Rev Chilena Infectol 2005; 22:247.</a></li><li><a class="nounderline abstract_t">Dorigo-Zetsma JW, Wilbrink B, van der Nat H, et al. Results of molecular detection of Mycoplasma pneumoniae among patients with acute respiratory infection and in their household contacts reveals children as human reservoirs. J Infect Dis 2001; 183:675.</a></li><li><a class="nounderline abstract_t">Linchevski I, Klement E, Nir-Paz R. Mycoplasma pneumoniae vaccine protective efficacy and adverse reactions--Systematic review and meta-analysis. Vaccine 2009; 27:2437.</a></li><li><a class="nounderline abstract_t">Centor RM, Atkinson TP, Ratliff AE, et al. The clinical presentation of Fusobacterium-positive and streptococcal-positive pharyngitis in a university health clinic: a cross-sectional study. Ann Intern Med 2015; 162:241.</a></li><li><a class="nounderline abstract_t">Mansel JK, Rosenow EC 3rd, Smith TF, Martin JW Jr. Mycoplasma pneumoniae pneumonia. Chest 1989; 95:639.</a></li><li><a class="nounderline abstract_t">Wadowsky RM, Castilla EA, Laus S, et al. Evaluation of Chlamydia pneumoniae and Mycoplasma pneumoniae as etiologic agents of persistent cough in adolescents and adults. J Clin Microbiol 2002; 40:637.</a></li><li><a class="nounderline abstract_t">Kawakami N, Namkoong H, Ohata T, et al. Clinical features of Mycoplasma pneumoniae pneumonia in older adults. Geriatr Gerontol Int 2018; 18:814.</a></li><li><a class="nounderline abstract_t">Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 5-1992. A 20-year-old man with diffuse pulmonary infiltrates and disseminated intravascular coagulation. N Engl J Med 1992; 326:324.</a></li><li><a class="nounderline abstract_t">Chan ED, Welsh CH. Fulminant Mycoplasma pneumoniae pneumonia. West J Med 1995; 162:133.</a></li><li><a class="nounderline abstract_t">Kannan TR, Hardy RD, Coalson JJ, et al. Fatal outcomes in family transmission of Mycoplasma pneumoniae. Clin Infect Dis 2012; 54:225.</a></li><li><a class="nounderline abstract_t">Valade S, Biard L, Lemiale V, et al. Severe atypical pneumonia in critically ill patients: a retrospective multicenter study. Ann Intensive Care 2018; 8:81.</a></li><li><a class="nounderline abstract_t">Loomes LM, Uemura K, Childs RA, et al. Erythrocyte receptors for Mycoplasma pneumoniae are sialylated oligosaccharides of Ii antigen type. Nature 1984; 307:560.</a></li><li><a class="nounderline abstract_t">Großhennig S, Ischebeck T, Gibhardt J, et al. Hydrogen sulfide is a novel potential virulence factor of Mycoplasma pneumoniae: characterization of the unusual cysteine desulfurase/desulfhydrase HapE. Mol Microbiol 2016; 100:42.</a></li><li><a class="nounderline abstract_t">Zafer MH, Gamel AS, Ansari MA, Hamid ME. Anemic crisis due to Mycoplasma pneumoniae complication in sickle cell patients. Saudi Med J 2009; 30:157.</a></li><li><a class="nounderline abstract_t">Daxböck F, Zedtwitz-Liebenstein K, Burgmann H, Graninger W. Severe hemolytic anemia and excessive leukocytosis masking mycoplasma pneumonia. Ann Hematol 2001; 80:180.</a></li><li><a class="nounderline abstract_t">Koskiniemi M. CNS manifestations associated with Mycoplasma pneumoniae infections: summary of cases at the University of Helsinki and review. Clin Infect Dis 1993; 17 Suppl 1:S52.</a></li><li><a class="nounderline abstract_t">Tsiodras S, Kelesidis I, Kelesidis T, et al. Central nervous system manifestations of Mycoplasma pneumoniae infections. J Infect 2005; 51:343.</a></li><li><a class="nounderline abstract_t">Coelho M, Leite A, Revés A, et al. Mycoplasma pneumoniae causing nervous system lesion and SIADH in the absence of pneumonia. Clin Neurol Neurosurg 2004; 106:129.</a></li><li><a class="nounderline abstract_t">Daxboeck F. Mycoplasma pneumoniae central nervous system infections. Curr Opin Neurol 2006; 19:374.</a></li><li><a class="nounderline abstract_t">Bitnun A, Ford-Jones E, Blaser S, Richardson S. Mycoplasma pneumoniae ecephalitis. Semin Pediatr Infect Dis 2003; 14:96.</a></li><li><a class="nounderline abstract_t">Smith R, Eviatar L. Neurologic manifestations of Mycoplasma pneumoniae infections: diverse spectrum of diseases. A report of six cases and review of the literature. Clin Pediatr (Phila) 2000; 39:195.</a></li><li><a class="nounderline abstract_t">Tong CY, Menson E, Lin JP, Lim M. Prevalence of mycoplasma encephalitis. Lancet Infect Dis 2011; 11:425.</a></li><li><a class="nounderline abstract_t">de Groot RCA, Meyer Sauteur PM, Unger WWJ, van Rossum AMC. Things that could be Mycoplasma pneumoniae. J Infect 2017; 74 Suppl 1:S95.</a></li><li><a class="nounderline abstract_t">Meyer Sauteur PM, Jacobs BC, Spuesens EB, et al. Antibody responses to Mycoplasma pneumoniae: role in pathogenesis and diagnosis of encephalitis? PLoS Pathog 2014; 10:e1003983.</a></li><li><a class="nounderline abstract_t">Powers JM, Johnson MD. Mycoplasmal panencephalitis: a neuropathologic documentation. Acta Neuropathol 2012; 124:143.</a></li><li><a class="nounderline abstract_t">Tsiodras S, Kelesidis T, Kelesidis I, et al. Mycoplasma pneumoniae-associated myelitis: a comprehensive review. Eur J Neurol 2006; 13:112.</a></li><li><a class="nounderline abstract_t">Tay YK, Huff JC, Weston WL. Mycoplasma pneumoniae infection is associated with Stevens-Johnson syndrome, not erythema multiforme (von Hebra). J Am Acad Dermatol 1996; 35:757.</a></li><li><a class="nounderline abstract_t">Curtiss P, Melnick L, Sicco KL, Liebman TN. Mycoplasma pneumoniae, more than a lung disease. Dermatol Online J 2018; 24.</a></li><li><a class="nounderline abstract_t">Bhoopalan SV, Chawla V, Hogan MB, et al. Bullous Skin Manifestations of Mycoplasma pneumoniae Infection: A Case Series. J Investig Med High Impact Case Rep 2017; 5:2324709617727759.</a></li><li><a class="nounderline abstract_t">Vujic I, Shroff A, Grzelka M, et al. Mycoplasma pneumoniae-associated mucositis--case report and systematic review of literature. J Eur Acad Dermatol Venereol 2015; 29:595.</a></li><li><a class="nounderline abstract_t">Amode R, Ingen-Housz-Oro S, Ortonne N, et al. Clinical and histologic features of Mycoplasma pneumoniae-related erythema multiforme: A single-center series of 33 cases compared with 100 cases induced by other causes. J Am Acad Dermatol 2018; 79:110.</a></li><li><a class="nounderline abstract_t">Olson D, Watkins LK, Demirjian A, et al. Outbreak of Mycoplasma pneumoniae-Associated Stevens-Johnson Syndrome. Pediatrics 2015; 136:e386.</a></li><li><a class="nounderline abstract_t">Szymanski M, Petric M, Saunders FE, Tellier R. Mycoplasma pneumoniae pericarditis demonstrated by polymerase chain reaction and electron microscopy. Clin Infect Dis 2002; 34:E16.</a></li><li><a class="nounderline abstract_t">Scapini JP, Flynn LP, Sciacaluga S, et al. Confirmed Mycoplasma pneumoniae endocarditis. Emerg Infect Dis 2008; 14:1664.</a></li><li><a class="nounderline abstract_t">Paz A, Potasman I. Mycoplasma-associated carditis. Case reports and review. Cardiology 2002; 97:83.</a></li><li><a class="nounderline abstract_t">Nagashima M, Higaki T, Satoh H, Nakano T. Cardiac thrombus associated with Mycoplasma pneumoniae infection. Interact Cardiovasc Thorac Surg 2010; 11:849.</a></li><li><a class="nounderline abstract_t">Levy PY, Corey R, Berger P, et al. Etiologic diagnosis of 204 pericardial effusions. Medicine (Baltimore) 2003; 82:385.</a></li><li><a class="nounderline abstract_t">Yang J, Zhao H, Yuan H, et al. Prevalence and association of mycoplasma infection in the development of coronary artery disease. Braz J Biol 2021; 83:e246385.</a></li><li><a class="nounderline abstract_t">Romero-Gómez M, Otero MA, Sánchez-Muñoz D, et al. Acute hepatitis due to Mycoplasma pneumoniae infection without lung involvement in adult patients. J Hepatol 2006; 44:827.</a></li><li><a class="nounderline abstract_t">Kim KW, Sung JJ, Tchah H, et al. Hepatitis associated with Mycoplasma pneumoniae infection in Korean children: a prospective study. Korean J Pediatr 2015; 58:211.</a></li><li><a class="nounderline abstract_t">Chaudhry R, Nisar N, Malhotra P, et al. Polymerase chain reaction confirmed Mycoplasma pneumoniae arthritis: a case report. Indian J Pathol Microbiol 2003; 46:433.</a></li><li><a class="nounderline abstract_t">Davis CP, Cochran S, Lisse J, et al. Isolation of Mycoplasma pneumoniae from synovial fluid samples in a patient with pneumonia and polyarthritis. Arch Intern Med 1988; 148:969.</a></li><li><a class="nounderline abstract_t">Weinstein O, Shneck M, Levy J, Lifshitz T. Bilateral acute anterior uveitis as a presenting symptom of Mycoplasma pneumoniae infection. Can J Ophthalmol 2006; 41:594.</a></li><li><a class="nounderline abstract_t">Yashar SS, Yashar B, Epstein E, Viani RM. Uveitis associated with Mycoplasma pneumoniae meningitis. Acta Ophthalmol Scand 2001; 79:100.</a></li><li><a class="nounderline abstract_t">Perry JT, Chen WS. Acute Mycoplasma pneumoniae infection presenting with unilateral anterior uveitis and perineuritis. J AAPOS 2016; 20:178.</a></li><li><a class="nounderline abstract_t">Vitullo BB, O'Regan S, de Chadarevian JP, Kaplan BS. Mycoplasma pneumonia associated with acute glomerulonephritis. Nephron 1978; 21:284.</a></li><li><a class="nounderline abstract_t">Carrara C, Abbate M, Sabadini E, Remuzzi G. Acute Kidney Injury and Hemolytic Anemia Secondary to Mycoplasma pneumoniae Infection. Nephron 2017; 137:148.</a></li><li><a class="nounderline abstract_t">Bar Meir E, Amital H, Levy Y, et al. Mycoplasma-pneumoniae-induced thrombotic thrombocytopenic purpura. Acta Haematol 2000; 103:112.</a></li><li><a class="nounderline abstract_t">Caeiro Alves F, Aguiar R, Pessegueiro P, Pires C. Thrombotic microangiopathy associated with Mycoplasma pneumoniae infection. BMJ Case Rep 2018; 2018.</a></li><li><a class="nounderline abstract_t">Khan FY, Sayed H. Rhabdomyolysis associated with Mycoplasma pneumoniae pneumonia. Hong Kong Med J 2012; 18:247.</a></li><li><a class="nounderline abstract_t">Oishi T, Narita M, Ohya H, et al. Rhabdomyolysis associated with antimicrobial drug-resistant Mycoplasma pneumoniae. Emerg Infect Dis 2012; 18:849.</a></li><li><a class="nounderline abstract_t">RIFKIND D, CHANOCK R, KRAVETZ H, et al. Ear involvement (myringitis) and primary atypical pneumonia following inoculation of volunteers with Eaton agent. Am Rev Respir Dis 1962; 85:479.</a></li><li><a class="nounderline abstract_t">Roberts DB. The etiology of bullous myringitis and the role of mycoplasmas in ear disease: a review. Pediatrics 1980; 65:761.</a></li><li><a class="nounderline abstract_t">Zha L, Shen J, Tefsen B, et al. Clinical features and outcomes of adult COVID-19 patients co-infected with Mycoplasma pneumoniae. J Infect 2020; 81:e12.</a></li><li><a class="nounderline abstract_t">Metlay JP, Waterer GW, Long AC, et al. Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med 2019; 200:e45.</a></li><li class="breakAll">Serum IgM and Molecular Tests for Mycoplasma pneumoniae Detection: A Review of Diagnostic Test Accuracy, Clinical Effectiveness, Cost-Effectiveness, and Guidelines, Canadian Agency for Drugs and Technologies in Health.</li><li><a class="nounderline abstract_t">Diaz MH, Benitez AJ, Cross KE, et al. Molecular Detection and Characterization of Mycoplasma pneumoniae Among Patients Hospitalized With Community-Acquired Pneumonia in the United States. Open Forum Infect Dis 2015; 2:ofv106.</a></li><li><a class="nounderline abstract_t">Stein B, DeCredico N, Hillman L. Evaluation of the Direct Antiglobulin Test (DAT) in the Setting of Mycoplasma pneumoniae Infection. JAMA 2018; 319:1377.</a></li><li><a class="nounderline abstract_t">Neeser OL, Vukajlovic T, Felder L, et al. A high C-reactive protein/procalcitonin ratio predicts Mycoplasma pneumoniae infection. Clin Chem Lab Med 2019; 57:1638.</a></li><li class="breakAll">Viruses, Mycoplasma, and Chlamydia. In: Imaging of Pulmonary Infections, Muller NL, Franquet, T, Lee KS, Silva CIS (Eds), Lippincott Williams and Wilkins, Philadelphia 2007. p.94.</li><li><a class="nounderline abstract_t">Saraya T, Ohkuma K, Tsukahara Y, et al. Correlation between clinical features, high-resolution computed tomography findings, and a visual scoring system in patients with pneumonia due to Mycoplasma pneumoniae. Respir Investig 2018; 56:320.</a></li><li><a class="nounderline abstract_t">Miyashita N, Sugiu T, Kawai Y, et al. Radiographic features of Mycoplasma pneumoniae pneumonia: differential diagnosis and performance timing. BMC Med Imaging 2009; 9:7.</a></li><li><a class="nounderline abstract_t">Nakanishi M, Nakashima K, Takeshita M, et al. Ability of high-resolution computed tomography to distinguish Mycoplasma pneumoniae pneumonia from other bacterial pneumonia: Significance of lateral bronchial lesions, less air bronchogram, and no peripheral predominance. Respir Investig 2020; 58:169.</a></li><li><a class="nounderline abstract_t">Meyer Sauteur PM, Goetschel P, Lautenschlager S. Mycoplasma pneumoniae and mucositis--part of the Stevens-Johnson syndrome spectrum. J Dtsch Dermatol Ges 2012; 10:740.</a></li><li><a class="nounderline abstract_t">Ji M, Lee NS, Oh JM, et al. Single-nucleotide polymorphism PCR for the detection of Mycoplasma pneumoniae and determination of macrolide resistance in respiratory samples. J Microbiol Methods 2014; 102:32.</a></li><li><a class="nounderline abstract_t">Ito Y, Iwashima S, Hayano S, et al. Rapid Detection of the Macrolide Sensitivity of Pneumonia-Causing Mycoplasma pneumoniae Using Quenching Probe Polymerase Chain Reaction (GENECUBE®). Mol Diagn Ther 2018; 22:737.</a></li><li><a class="nounderline abstract_t">Ando M, Morozumi M, Adachi Y, et al. Multilocus Sequence Typing of Mycoplasma pneumoniae, Japan, 2002-2016. Emerg Infect Dis 2018; 24:1895.</a></li><li><a class="nounderline abstract_t">Liu Y, Ye X, Zhang H, et al. Rapid detection of Mycoplasma pneumoniae and its macrolide-resistance mutation by Cycleave PCR. Diagn Microbiol Infect Dis 2014; 78:333.</a></li><li><a class="nounderline abstract_t">Robert S, Lhommet C, Le Brun C, et al. Diagnostic performance of multiplex PCR on pulmonary samples versus nasopharyngeal aspirates in community-acquired severe lower respiratory tract infections. J Clin Virol 2018; 108:1.</a></li><li class="breakAll">US Food and Drug Administration (FDA) News Release. FDA expands use for FilmArray Respiratory Panel. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm304177.htm (Accessed on June 11, 2012).</li><li><a class="nounderline abstract_t">Poritz MA, Blaschke AJ, Byington CL, et al. FilmArray, an automated nested multiplex PCR system for multi-pathogen detection: development and application to respiratory tract infection. PLoS One 2011; 6:e26047.</a></li><li><a class="nounderline abstract_t">Ruggiero P, McMillen T, Tang YW, Babady NE. Evaluation of the BioFire FilmArray respiratory panel and the GenMark eSensor respiratory viral panel on lower respiratory tract specimens. J Clin Microbiol 2014; 52:288.</a></li><li><a class="nounderline abstract_t">Baron EJ, Miller JM, Weinstein MP, et al. A guide to utilization of the microbiology laboratory for diagnosis of infectious diseases: 2013 recommendations by the Infectious Diseases Society of America (IDSA) and the American Society for Microbiology (ASM). Clin Infect Dis 2013; 57:e22.</a></li><li><a class="nounderline abstract_t">Leal SM Jr, Totten AH, Xiao L, et al. Evaluation of Commercial Molecular Diagnostic Methods for Detection and Determination of Macrolide Resistance in Mycoplasma pneumoniae. J Clin Microbiol 2020; 58.</a></li><li><a class="nounderline abstract_t">Shi W, Wei M, Wang Q, et al. Rapid diagnosis of Mycoplasma pneumonia infection by denaturation bubble-mediated strand exchange amplification: comparison with LAMP and real-time PCR. Sci Rep 2019; 9:896.</a></li><li><a class="nounderline abstract_t">Blackmore TK, Reznikov M, Gordon DL. Clinical utility of the polymerase chain reaction to diagnose Mycoplasma pneumoniae infection. Pathology 1995; 27:177.</a></li><li><a class="nounderline abstract_t">Waring AL, Halse TA, Csiza CK, et al. Development of a genomics-based PCR assay for detection of Mycoplasma pneumoniae in a large outbreak in New York State. J Clin Microbiol 2001; 39:1385.</a></li><li><a class="nounderline abstract_t">Kanwar N, Pence MA, Mayne D, et al. Evaluation of the illumigene Mycoplasma Direct DNA Amplification Assay. J Clin Microbiol 2018; 56.</a></li><li><a class="nounderline abstract_t">Zhang L, Zong ZY, Liu YB, et al. PCR versus serology for diagnosing Mycoplasma pneumoniae infection: a systematic review &amp; meta-analysis. Indian J Med Res 2011; 134:270.</a></li><li><a class="nounderline abstract_t">Thurman KA, Walter ND, Schwartz SB, et al. Comparison of laboratory diagnostic procedures for detection of Mycoplasma pneumoniae in community outbreaks. Clin Infect Dis 2009; 48:1244.</a></li><li><a class="nounderline abstract_t">Xiao F, Zhou J, Sun C, et al. Loop-Mediated Isothermal Amplification Coupled With Nanoparticle-Based Biosensor: A Rapid and Sensitive Method to Detect Mycoplasma pneumoniae. Front Cell Infect Microbiol 2022; 12:882855.</a></li><li><a class="nounderline abstract_t">Daxboeck F, Krause R, Wenisch C. Laboratory diagnosis of Mycoplasma pneumoniae infection. Clin Microbiol Infect 2003; 9:263.</a></li><li><a class="nounderline abstract_t">Nir-Paz R, Michael-Gayego A, Ron M, Block C. Evaluation of eight commercial tests for Mycoplasma pneumoniae antibodies in the absence of acute infection. Clin Microbiol Infect 2006; 12:685.</a></li><li><a class="nounderline abstract_t">Beersma MF, Dirven K, van Dam AP, et al. Evaluation of 12 commercial tests and the complement fixation test for Mycoplasma pneumoniae-specific immunoglobulin G (IgG) and IgM antibodies, with PCR used as the "gold standard". J Clin Microbiol 2005; 43:2277.</a></li><li><a class="nounderline abstract_t">Lee SC, Youn YS, Rhim JW, et al. Early Serologic Diagnosis of Mycoplasma pneumoniae Pneumonia: An Observational Study on Changes in Titers of Specific-IgM Antibodies and Cold Agglutinins. Medicine (Baltimore) 2016; 95:e3605.</a></li><li><a class="nounderline abstract_t">Critchley IA, Jones ME, Heinze PD, et al. In vitro activity of levofloxacin against contemporary clinical isolates of Legionella pneumophila, Mycoplasma pneumoniae and Chlamydia pneumoniae from North America and Europe. Clin Microbiol Infect 2002; 8:214.</a></li><li><a class="nounderline abstract_t">Pereyre S, Guyot C, Renaudin H, et al. In vitro selection and characterization of resistance to macrolides and related antibiotics in Mycoplasma pneumoniae. Antimicrob Agents Chemother 2004; 48:460.</a></li><li><a class="nounderline abstract_t">Schönwald S, Gunjaca M, Kolacny-Babić L, et al. Comparison of azithromycin and erythromycin in the treatment of atypical pneumonias. J Antimicrob Chemother 1990; 25 Suppl A:123.</a></li><li><a class="nounderline abstract_t">File TM Jr, Segreti J, Dunbar L, et al. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrob Agents Chemother 1997; 41:1965.</a></li><li><a class="nounderline abstract_t">Finch R, Schürmann D, Collins O, et al. Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment. Antimicrob Agents Chemother 2002; 46:1746.</a></li><li><a class="nounderline abstract_t">Kawai Y, Miyashita N, Kubo M, et al. Therapeutic efficacy of macrolides, minocycline, and tosufloxacin against macrolide-resistant Mycoplasma pneumoniae pneumonia in pediatric patients. Antimicrob Agents Chemother 2013; 57:2252.</a></li><li class="breakAll">Holzman RS and Simberkoff MS. Mycoplasma pneumoniae and Atypical Pneumonia. In: Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 8, Bennett JE, Dolin R and Blaser MJ (Eds), Elsevier, Inc, Philadelphia 2015. p.2183.</li><li><a class="nounderline abstract_t">Smith CB, Friedewald WT, Chanock RM. Shedding of Mycoplasma pneumoniae after tetracycline and erythromycin therapy. N Engl J Med 1967; 276:1172.</a></li><li><a class="nounderline abstract_t">Gücüyener K, Simşek F, Yilmaz O, Serdaroğlu A. Methyl-prednisolone in neurologic complications of Mycoplasma pneumonia. Indian J Pediatr 2000; 67:467.</a></li><li><a class="nounderline abstract_t">Baheerathan A, Ross Russell A, Bremner F, Farmer SF. A Rare Case of Bilateral Optic Neuritis and Guillain-Barré Syndrome Post Mycoplasma pneumoniae Infection. Neuroophthalmology 2017; 41:41.</a></li><li><a class="nounderline abstract_t">Wandro C, Dolatshahi L, Blackall D. Severe Warm Autoimmune Hemolytic Anemia in a 7-Month-Old Infant Associated With a Mycoplasma Pneumoniae Infection. J Pediatr Hematol Oncol 2018; 40:e439.</a></li><li><a class="nounderline abstract_t">Kim K, Jung S, Kim M, et al. Global Trends in the Proportion of Macrolide-Resistant Mycoplasma pneumoniae Infections: A Systematic Review and Meta-analysis. JAMA Netw Open 2022; 5:e2220949.</a></li><li><a class="nounderline abstract_t">Kawai Y, Miyashita N, Kubo M, et al. Nationwide surveillance of macrolide-resistant Mycoplasma pneumoniae infection in pediatric patients. Antimicrob Agents Chemother 2013; 57:4046.</a></li><li><a class="nounderline abstract_t">Zhao F, Lv M, Tao X, et al. Antibiotic sensitivity of 40 Mycoplasma pneumoniae isolates and molecular analysis of macrolide-resistant isolates from Beijing, China. Antimicrob Agents Chemother 2012; 56:1108.</a></li><li><a class="nounderline abstract_t">Peuchant O, Ménard A, Renaudin H, et al. Increased macrolide resistance of Mycoplasma pneumoniae in France directly detected in clinical specimens by real-time PCR and melting curve analysis. J Antimicrob Chemother 2009; 64:52.</a></li><li><a class="nounderline abstract_t">Wolff BJ, Thacker WL, Schwartz SB, Winchell JM. Detection of macrolide resistance in Mycoplasma pneumoniae by real-time PCR and high-resolution melt analysis. Antimicrob Agents Chemother 2008; 52:3542.</a></li><li><a class="nounderline abstract_t">Zheng X, Lee S, Selvarangan R, et al. Macrolide-Resistant Mycoplasma pneumoniae, United States. Emerg Infect Dis 2015; 21:1470.</a></li><li><a class="nounderline abstract_t">Waites KB, Ratliff A, Crabb DM, et al. Macrolide-Resistant Mycoplasma pneumoniae in the United States as Determined from a National Surveillance Program. J Clin Microbiol 2019; 57.</a></li><li><a class="nounderline abstract_t">Rothstein TE, Cunningham SA, Rieke RA, et al. Macrolide Resistance in Mycoplasma pneumoniae, Midwestern United States, 2014 to 2021. Antimicrob Agents Chemother 2022; 66:e0243221.</a></li><li><a class="nounderline abstract_t">Lee YR, Jacobs KL. Leave it to Lefamulin: A Pleuromutilin Treatment Option in Community-Acquired Bacterial Pneumonia. Drugs 2019; 79:1867.</a></li><li><a class="nounderline abstract_t">Yuan X, Liu J, Bai C, et al. Tigecycline in the treatment of fulminant Mycoplasma pneumoniae pneumonia non-responsive to azithromycin and fluoroquinolone: A case report. Medicine (Baltimore) 2020; 99:e21128.</a></li><li class="breakAll">Siegel JD, Rhinehart E, Jackson M, Chiarello L. Healthcare Infection Control Practices Advisory Committee 2007 guideline for isolation precautions: Preventing transmission of infectious agents in healthcare settings, June 2007. http://www.cdc.gov/hicpac/2007IP/2007isolationPrecautions.html (Accessed on November 26, 2008).</li><li><a class="nounderline abstract_t">Gdalevich M, Haas EJ, Dukhan L, et al. Control of a Mycoplasma pneumoniae Outbreak in an Institutional Setting Using Azithromycin Prophylaxis. Front Public Health 2017; 5:366.</a></li></ol></div><div id="topicVersionRevision">Topic 6989 Version 50.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8909826" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Infections due to species of Mycoplasma and Ureaplasma: an update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25344534" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Genomic Investigations unmask Mycoplasma amphoriforme, a new respiratory pathogen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30051803" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Mycoplasma amphoriforme vs M. pneumoniae: similarities and differences between patient characteristics in a regional hospital in the Netherlands.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9126441" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Mycoplasmas: sophisticated, reemerging, and burdened by their notoriety.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14763969" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Cellular engineering in a minimal microbe: structure and assembly of the terminal organelle of Mycoplasma pneumoniae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23396910" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Protein kinase/phosphatase function correlates with gliding motility in Mycoplasma pneumoniae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8876531" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Carbohydrate recognition by Mycoplasma pneumoniae and pathologic consequences.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8876532" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Interplay between mycoplasma surface proteins, airway cells, and the protean manifestations of mycoplasma-mediated human infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12007626" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : A lipoprotein family from Mycoplasma fermentans confers host immune activation through Toll-like receptor 2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12065522" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : In vivo effects of a synthetic 2-kilodalton macrophage-activating lipopeptide of Mycoplasma fermentans after pulmonary application.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15110799" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Cytokines in Mycoplasma pneumoniae infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33930194" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Biological functions of IL-17-producing cells in mycoplasma respiratory infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15063492" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Internalization and intracellular survival of Mycoplasma pneumoniae by non-phagocytic cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19389769" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Sequence variations in RepMP2/3 and RepMP4 elements reveal intragenomic homologous DNA recombination events in Mycoplasma pneumoniae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16617115" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : ADP-ribosylating and vacuolating cytotoxin of Mycoplasma pneumoniae represents unique virulence determinant among bacterial pathogens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26335586" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Comparative "-omics" in Mycoplasma pneumoniae Clinical Isolates Reveals Key Virulence Factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34867898" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Community-Acquired Respiratory Distress Syndrome Toxin: Unique Exotoxin for M. pneumoniae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35505407" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Investigation of the relationship between community-acquired respiratory distress syndrome toxin and the high-mobility group box protein 1-toll-like receptors-myeloid differentiation factor 88 signaling pathway in Mycoplasma pneumoniae pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23412845" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Type 1 and type 2 strains of Mycoplasma pneumoniae form different biofilms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1955701" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Atypical pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1906790" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Pneumonia caused by Mycoplasma pneumoniae infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23690754" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Carriage of Mycoplasma pneumoniae in the upper respiratory tract of symptomatic and asymptomatic children: an observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18547431" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Polymerase chain reaction is superior to serology for the diagnosis of acute Mycoplasma pneumoniae infection and reveals a high rate of persistent infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29155483" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Modelling persistent Mycoplasma pneumoniae infection of human airway epithelium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34561284" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Mycoplasma pneumoniae carriage evades induction of protective mucosal antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/448195" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Long-term epidemiology of infections with Mycoplasma pneumoniae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11979130" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Mycoplasma pneumoniae infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8435028" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Mycoplasma pneumoniae pneumonia requiring hospitalization, with emphasis on infection in the elderly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11493128" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Nonsevere community-acquired pneumonia: correlation between cause and severity or comorbidity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12718823" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Prospective epidemiologic survey of patients with community-acquired pneumonia requiring hospitalization in Switzerland.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25887603" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Etiology of community-acquired pneumonia and diagnostic yields of microbiological methods: a 3-year prospective study in Norway.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20014950" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Etiology of community-acquired pneumonia: increased microbiological yield with new diagnostic methods.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8884996" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Mycoplasma pneumoniae community-acquired pneumonia: a review of 101 hospitalized adult patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7839256" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : 'Atypical' bacteria are a common cause of community-acquired pneumonia in hospitalised adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12740268" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Community-acquired pneumonia in southeast Asia: the microbial differences between ambulatory and hospitalized patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26172429" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15672850" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Etiology of community-acquired pneumonia treated in an ambulatory setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29479548" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Incidence, Etiology, and Outcomes of Community-Acquired Pneumonia: A Population-Based Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29479548" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Incidence, Etiology, and Outcomes of Community-Acquired Pneumonia: A Population-Based Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25714161" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Community-acquired pneumonia requiring hospitalization among U.S. children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8399935" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Clinical overview of typical Mycoplasma pneumoniae infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26124847" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Epidemiological comparison of three Mycoplasma pneumoniae pneumonia epidemics in a single hospital over 10 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30016939" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Epidemiological characterization of respiratory tract infections caused by Mycoplasma pneumoniae during epidemic and post-epidemic periods in North China, from 2011 to 2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26909073" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Mycoplasma pneumoniae Epidemiology in England and Wales: A National Perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11693516" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Culturally verified Mycoplasma pneumoniae pneumonia in Japan: a long-term observation from 1979-99.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25355769" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Investigations of Mycoplasma pneumoniae infections in the United States: trends in molecular typing and macrolide resistance from 2006 to 2013.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9258572" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : A seroepidemiological study of Mycoplasma pneumoniae infections in Denmark over the 50-year period 1946-1995.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23624834" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Transmission of macrolide-resistant Mycoplasma pneumoniae within a family.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18808334" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Community outbreak of Mycoplasma pneumoniae infection: school-based cluster of neurologic disease associated with household transmission of respiratory illness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24371236" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Detection and characterization of Mycoplasma pneumoniae during an outbreak of respiratory illness at a university.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/528761" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : A college epidemic of Mycoplasma pneumoniae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23903594" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Mycoplasma pneumoniae outbreak at a university - Georgia, 2012.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9419183" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Enhanced control of an outbreak of Mycoplasma pneumoniae pneumonia with azithromycin prophylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11237807" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Azithromycin prophylaxis during a hospital outbreak of Mycoplasma pneumoniae pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25811678" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Mycoplasma pneumoniae outbreak in a long-term care facility--Nebraska, 2014.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11528569" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Randomized, placebo-controlled clinical trial of oral azithromycin prophylaxis against respiratory infections in a high-risk, young adult population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17051486" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Identification of risk factors for infection in an outbreak of Mycoplasma pneumoniae respiratory tract disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10585810" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : An outbreak of acute respiratory disease caused by Mycoplasma pneumoniae and adenovirus at a federal service training academy: new implications from an old scenario.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11300629" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Outbreak of community-acquired pneumonia caused by Mycoplasma pneumoniae--Colorado, 2000.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22401504" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Ongoing epidemic of Mycoplasma pneumoniae infection in Jerusalem, Israel, 2010 to 2012.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31964459" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Mycoplasma pneumoniae infections, 11 countries in Europe and Israel, 2011 to 2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25693633" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Mycoplasma pneumoniae and Chlamydia spp. infection in community-acquired pneumonia, Germany, 2011-2012.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23279613" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : The increased incidence of Mycoplasma pneumoniae in France in 2011 was polyclonal, mainly involving M. pneumoniae type 1 strains.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22321135" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Increased incidence of Mycoplasma pneumoniae infection in Finland, 2010-2011.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22340973" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Increased detection of Mycoplasma pneumoniae infection in children in England and Wales, October 2011 to January 2012.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5100980" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Mycoplasma pneumoniae disease: clinical spectrum, pathophysiology, epidemiology, and control.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28539503" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Mycoplasma pneumoniae from the Respiratory Tract and Beyond.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16077892" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : [Asymptomatic pharyngeal carriage of Mycoplasma pneumoniae in Chilean children].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11170998" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Results of molecular detection of Mycoplasma pneumoniae among patients with acute respiratory infection and in their household contacts reveals children as human reservoirs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19368785" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Mycoplasma pneumoniae vaccine protective efficacy and adverse reactions--Systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25686164" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : The clinical presentation of Fusobacterium-positive and streptococcal-positive pharyngitis in a university health clinic: a cross-sectional study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2646077" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Mycoplasma pneumoniae pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11825984" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Evaluation of Chlamydia pneumoniae and Mycoplasma pneumoniae as etiologic agents of persistent cough in adolescents and adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29722163" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Clinical features of Mycoplasma pneumoniae pneumonia in older adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1728737" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 5-1992. A 20-year-old man with diffuse pulmonary infiltrates and disseminated intravascular coagulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7725685" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Fulminant Mycoplasma pneumoniae pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22052890" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Fatal outcomes in family transmission of Mycoplasma pneumoniae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30105627" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Severe atypical pneumonia in critically ill patients: a retrospective multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6420710" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Erythrocyte receptors for Mycoplasma pneumoniae are sialylated oligosaccharides of Ii antigen type.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26711628" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Hydrogen sulfide is a novel potential virulence factor of Mycoplasma pneumoniae: characterization of the unusual cysteine desulfurase/desulfhydrase HapE.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19139793" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Anemic crisis due to Mycoplasma pneumoniae complication in sickle cell patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11320906" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Severe hemolytic anemia and excessive leukocytosis masking mycoplasma pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8399938" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : CNS manifestations associated with Mycoplasma pneumoniae infections: summary of cases at the University of Helsinki and review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16181677" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Central nervous system manifestations of Mycoplasma pneumoniae infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15003304" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Mycoplasma pneumoniae causing nervous system lesion and SIADH in the absence of pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16914976" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Mycoplasma pneumoniae central nervous system infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12881797" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Mycoplasma pneumoniae ecephalitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10791130" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Neurologic manifestations of Mycoplasma pneumoniae infections: diverse spectrum of diseases. A report of six cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21616452" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Prevalence of mycoplasma encephalitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28646969" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Things that could be Mycoplasma pneumoniae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24945969" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Antibody responses to Mycoplasma pneumoniae: role in pathogenesis and diagnosis of encephalitis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22370906" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Mycoplasmal panencephalitis: a neuropathologic documentation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16490040" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Mycoplasma pneumoniae-associated myelitis: a comprehensive review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8912572" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Mycoplasma pneumoniae infection is associated with Stevens-Johnson syndrome, not erythema multiforme (von Hebra).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30142726" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Mycoplasma pneumoniae, more than a lung disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28959692" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Bullous Skin Manifestations of Mycoplasma pneumoniae Infection: A Case Series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24665876" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Mycoplasma pneumoniae-associated mucositis--case report and systematic review of literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29559400" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Clinical and histologic features of Mycoplasma pneumoniae-related erythema multiforme: A single-center series of 33 cases compared with 100 cases induced by other causes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26216320" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Outbreak of Mycoplasma pneumoniae-Associated Stevens-Johnson Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11731968" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Mycoplasma pneumoniae pericarditis demonstrated by polymerase chain reaction and electron microscopy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18826843" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Confirmed Mycoplasma pneumoniae endocarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11978954" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Mycoplasma-associated carditis. Case reports and review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20847069" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Cardiac thrombus associated with Mycoplasma pneumoniae infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14663288" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Etiologic diagnosis of 204 pericardial effusions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34524372" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Prevalence and association of mycoplasma infection in the development of coronary artery disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16483682" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Acute hepatitis due to Mycoplasma pneumoniae infection without lung involvement in adult patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26213549" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Hepatitis associated with Mycoplasma pneumoniae infection in Korean children: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15025294" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Polymerase chain reaction confirmed Mycoplasma pneumoniae arthritis: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3128197" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Isolation of Mycoplasma pneumoniae from synovial fluid samples in a patient with pneumonia and polyarthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17016530" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Bilateral acute anterior uveitis as a presenting symptom of Mycoplasma pneumoniae infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11167302" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Uveitis associated with Mycoplasma pneumoniae meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27079602" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Acute Mycoplasma pneumoniae infection presenting with unilateral anterior uveitis and perineuritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/152413" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Mycoplasma pneumonia associated with acute glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28683450" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Acute Kidney Injury and Hemolytic Anemia Secondary to Mycoplasma pneumoniae Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10838456" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Mycoplasma-pneumoniae-induced thrombotic thrombocytopenic purpura.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29550758" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Thrombotic microangiopathy associated with Mycoplasma pneumoniae infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22665690" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Rhabdomyolysis associated with Mycoplasma pneumoniae pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22515975" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Rhabdomyolysis associated with antimicrobial drug-resistant Mycoplasma pneumoniae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14492218" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Ear involvement (myringitis) and primary atypical pneumonia following inoculation of volunteers with Eaton agent.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7367083" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : The etiology of bullous myringitis and the role of mycoplasmas in ear disease: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32652163" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Clinical features and outcomes of adult COVID-19 patients co-infected with Mycoplasma pneumoniae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31573350" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31573350" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26284257" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Molecular Detection and Characterization of Mycoplasma pneumoniae Among Patients Hospitalized With Community-Acquired Pneumonia in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29614161" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Evaluation of the Direct Antiglobulin Test (DAT) in the Setting of Mycoplasma pneumoniae Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31128571" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : A high C-reactive protein/procalcitonin ratio predicts Mycoplasma pneumoniae infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31128571" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : A high C-reactive protein/procalcitonin ratio predicts Mycoplasma pneumoniae infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29764747" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Correlation between clinical features, high-resolution computed tomography findings, and a visual scoring system in patients with pneumonia due to Mycoplasma pneumoniae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19400968" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Radiographic features of Mycoplasma pneumoniae pneumonia: differential diagnosis and performance timing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32146120" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Ability of high-resolution computed tomography to distinguish Mycoplasma pneumoniae pneumonia from other bacterial pneumonia: Significance of lateral bronchial lesions, less air bronchogram, and no peripheral predominance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22672205" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Mycoplasma pneumoniae and mucositis--part of the Stevens-Johnson syndrome spectrum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24780151" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Single-nucleotide polymorphism PCR for the detection of Mycoplasma pneumoniae and determination of macrolide resistance in respiratory samples.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30259422" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Rapid Detection of the Macrolide Sensitivity of Pneumonia-Causing Mycoplasma pneumoniae Using Quenching Probe Polymerase Chain Reaction (GENECUBE®).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30226158" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Multilocus Sequence Typing of Mycoplasma pneumoniae, Japan, 2002-2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24503503" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Rapid detection of Mycoplasma pneumoniae and its macrolide-resistance mutation by Cycleave PCR.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30195090" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Diagnostic performance of multiplex PCR on pulmonary samples versus nasopharyngeal aspirates in community-acquired severe lower respiratory tract infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30195090" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Diagnostic performance of multiplex PCR on pulmonary samples versus nasopharyngeal aspirates in community-acquired severe lower respiratory tract infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22039434" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : FilmArray, an automated nested multiplex PCR system for multi-pathogen detection: development and application to respiratory tract infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24131685" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Evaluation of the BioFire FilmArray respiratory panel and the GenMark eSensor respiratory viral panel on lower respiratory tract specimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23845951" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : A guide to utilization of the microbiology laboratory for diagnosis of infectious diseases: 2013 recommendations by the Infectious Diseases Society of America (IDSA) and the American Society for Microbiology (ASM).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32269102" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Evaluation of Commercial Molecular Diagnostic Methods for Detection and Determination of Macrolide Resistance in Mycoplasma pneumoniae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30696841" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Rapid diagnosis of Mycoplasma pneumonia infection by denaturation bubble-mediated strand exchange amplification: comparison with LAMP and real-time PCR.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7567149" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Clinical utility of the polymerase chain reaction to diagnose Mycoplasma pneumoniae infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11283060" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Development of a genomics-based PCR assay for detection of Mycoplasma pneumoniae in a large outbreak in New York State.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29720432" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Evaluation of the illumigene Mycoplasma Direct DNA Amplification Assay.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21985809" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : PCR versus serology for diagnosing Mycoplasma pneumoniae infection: a systematic review&amp;meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19331586" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Comparison of laboratory diagnostic procedures for detection of Mycoplasma pneumoniae in community outbreaks.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35873146" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : Loop-Mediated Isothermal Amplification Coupled With Nanoparticle-Based Biosensor: A Rapid and Sensitive Method to Detect Mycoplasma pneumoniae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12667235" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : Laboratory diagnosis of Mycoplasma pneumoniae infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16774570" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : Evaluation of eight commercial tests for Mycoplasma pneumoniae antibodies in the absence of acute infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15872256" id="rid150" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>151 : Evaluation of 12 commercial tests and the complement fixation test for Mycoplasma pneumoniae-specific immunoglobulin G (IgG) and IgM antibodies, with PCR used as the "gold standard".</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27175666" id="rid151" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>152 : Early Serologic Diagnosis of Mycoplasma pneumoniae Pneumonia: An Observational Study on Changes in Titers of Specific-IgM Antibodies and Cold Agglutinins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12047413" id="rid152" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>153 : In vitro activity of levofloxacin against contemporary clinical isolates of Legionella pneumophila, Mycoplasma pneumoniae and Chlamydia pneumoniae from North America and Europe.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14742195" id="rid153" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>154 : In vitro selection and characterization of resistance to macrolides and related antibiotics in Mycoplasma pneumoniae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2154431" id="rid154" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>155 : Comparison of azithromycin and erythromycin in the treatment of atypical pneumonias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9303395" id="rid155" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>156 : A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12019085" id="rid156" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>157 : Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23459497" id="rid157" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>158 : Therapeutic efficacy of macrolides, minocycline, and tosufloxacin against macrolide-resistant Mycoplasma pneumoniae pneumonia in pediatric patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23459497" id="rid158" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>159 : Therapeutic efficacy of macrolides, minocycline, and tosufloxacin against macrolide-resistant Mycoplasma pneumoniae pneumonia in pediatric patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6023234" id="rid159" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>160 : Shedding of Mycoplasma pneumoniae after tetracycline and erythromycin therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10932970" id="rid160" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>161 : Methyl-prednisolone in neurologic complications of Mycoplasma pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28228838" id="rid161" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>162 : A Rare Case of Bilateral Optic Neuritis and Guillain-BarréSyndrome Post Mycoplasma pneumoniae Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29135841" id="rid162" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>163 : Severe Warm Autoimmune Hemolytic Anemia in a 7-Month-Old Infant Associated With a Mycoplasma Pneumoniae Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35816304" id="rid163" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>164 : Global Trends in the Proportion of Macrolide-Resistant Mycoplasma pneumoniae Infections: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23716043" id="rid164" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>165 : Nationwide surveillance of macrolide-resistant Mycoplasma pneumoniae infection in pediatric patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22106216" id="rid165" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>166 : Antibiotic sensitivity of 40 Mycoplasma pneumoniae isolates and molecular analysis of macrolide-resistant isolates from Beijing, China.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19429926" id="rid166" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>167 : Increased macrolide resistance of Mycoplasma pneumoniae in France directly detected in clinical specimens by real-time PCR and melting curve analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18644962" id="rid167" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>168 : Detection of macrolide resistance in Mycoplasma pneumoniae by real-time PCR and high-resolution melt analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26196107" id="rid168" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>169 : Macrolide-Resistant Mycoplasma pneumoniae, United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31484701" id="rid169" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>170 : Macrolide-Resistant Mycoplasma pneumoniae in the United States as Determined from a National Surveillance Program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35311520" id="rid170" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>171 : Macrolide Resistance in Mycoplasma pneumoniae, Midwestern United States, 2014 to 2021.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31705486" id="rid171" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>172 : Leave it to Lefamulin: A Pleuromutilin Treatment Option in Community-Acquired Bacterial Pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32664140" id="rid172" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>173 : Tigecycline in the treatment of fulminant Mycoplasma pneumoniae pneumonia non-responsive to azithromycin and fluoroquinolone: A case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32664140" id="rid173" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>174 : Tigecycline in the treatment of fulminant Mycoplasma pneumoniae pneumonia non-responsive to azithromycin and fluoroquinolone: A case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29404316" id="rid174" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>175 : Control of a Mycoplasma pneumoniae Outbreak in an Institutional Setting Using Azithromycin Prophylaxis.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
